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Preface 
This journey began in 2009 during my cardiology training at Aal-
borg University Hospital. I was fortunate enough to be approached 
by Anna Margrethe Thøgersen who proposed me to write a case 
report on a patient with a pacemaker functioning normally despite 
exposure to a relatively high radiation dose. At that time, it ap-
peared that there were a rather limited number of studies present 
on the effects of ionizing radiation on heart rhythm devices. During 
the initial stage of working on the case report, cooperation with 
Sam Riahi and Annette Ross Jakobsen was established as well. This 
lead to our next work, where we conducted a survey of Danish 
radiotherapy and cardiology departments aiming to elucidate 
practical treatment of patients with a pacemaker or an implantable 
cardioverter defibrillator undergoing radiotherapy. Afterwards, we 
resolved to keep working in the field, as the number of pacemaker 
patients undergoing radiotherapy appeared to be increasing, and 
there still seemed to be numerous aspects to be explored. 
 Enrolled as a PhD student in September 2012, I had the great 
privilege to have Sam Riahi as my main academic advisor. He 
guided and supported me through the whole project with great 
enthusiasm. Sam’s inspiring commitment and his ability to show 
the way by seeing solutions in every challenge made this endeavor 
an exciting experience. I am grateful to Sam for introducing me to 
Mette Søgaard, who as my academic advisor played a key role in 
the epidemiological aspects of the study and made invaluable 
contributions during the writing process. I would also like to ac-
knowledge and thank Anna Margrethe Thøgersen for sharing her 
great ideas and for being a great academic advisor always ready to 
discuss both small details and large questions of the project. Her 
practical electrophysiology skills were essential during our experi-
ments. 
 Very special thanks go to Annette Ross Jakobsen who has been 
a fantastic colleague and partner, and who used tremendous 
amounts of her time and efforts during the experiments and data 
collection. Being the only physicist in our group, she played a pi-
votal role in guiding me through the technological aspects of radio-
therapy. I owe also many thanks to Benedict Kjærgaard and his 
great team from the Biomedical Research Laboratory, Aalborg 
University Hospital, for their commitment, immense practical help 
during the in vivo study, and for making complex things possible 
and fun. 
 Furthermore, I thank all colleagues at cardiology and radiothe-
rapy departments in Western Denmark for their enthusiasm and 
help during the data collection. It has been a great pleasure to 
work with you during this project. I am especially indebted to Peter 
Skogholt, Oncology Department, Vejle Hospital, for assisting with 
extraction of archived radiotherapy data. 
 In particular I would like to thank Søren Pihlkjær Hjortsøj, the 
head of the Department of Cardiology, Aalborg University Hospital, 
for supporting me during the study and for allocating time for the 
project when it was most needed. I am also grateful to professor 
Erik Berg Schmidt for his assistance and practical guidance during 
the PhD study and to Lars Oddershede, Martin Berg Johansen, and 
Søren Lundbye-Christensen for their statistical support. I thank 
Lærke Bruun Madsen for her help during data collection in the 
epidemiology study. I also owe a big thank to Hanne Madsen for 
revising the manuscripts. Great thanks go as well to the rest of my 
colleagues at the Department of Cardiology, Aalborg University 
Hospital; amongst them, I thank fellow PhD student Jacob Moes-
gaard Larsen for the encouragement and helpful insights. 
 I am grateful to the manufacturers for donating pacemakers 
and implantable cardioverter defibrillators for the project: Biotro-
nik, Boston Scientific, Medtronic, Sorin, and St. Jude Medical. 
 Last, but definitely not the least, I would like to thank my 
charming wife Sandra and our two great sons Gustas and Ignas. 
Only your love and tremendous support have made it all possible. 
 
Tomas Zaremba 
February 2015
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Abbreviations 
AAI  single chamber atrial pacemaker 
AAPM TG-34  American Association of Physicists in Medicine Task 
Group No. 34 
AMI  acute myocardial infarction 
ATP  antitachycardia pacing 
bpm  beats per minute 
CI   confidence interval 
CMOS  complementary metal oxide semiconductor 
Co   cobalt 
CRT  cardiac resynchronization therapy 
CRT-D  cardiac resynchronization therapy defibrillator 
CRT-P  cardiac resynchronization therapy pacemaker 
CT   computed tomography 
DDD  dual chamber pacemaker 
DDD-ICD dual chamber implantable cardioverter defibrillator 
DNPR  Danish National Patient Registry 
EMI  electromagnetic interference 
ERI  elective replacement indicator 
eV   electronvolt 
Gy   gray 
HR   hazard ratio 
ICD  implantable cardioverter defibrillator 
IQR  interquartile range 
kV   kilovolt 
LINAC  linear accelerator 
LET  linear energy transfer 
MeV  megaelectronvolt 
MRI  magnetic resonance imaging 
MV  megavolt 
OR   odds ratio 
PM  pacemaker 
RT   radiotherapy 
RRT  recommended replacement time 
VDD  single chamber pacemaker with ventricular lead and 
dual chamber sensing 
VF   ventricular fibrillation 
VHR  ventricular high-rate episode 
VT   ventricular tachycardia 
VVI  single chamber pacemaker with ventricular lead 
VVI-ICD single chamber implantable cardioverter defibrillator 
 
 
 
 
 
 
 
 
 
 
 
 
Radiotherapy in patients with pacemakers and implantable cardioverter defibrillators 5 
Introduction 
Since the first implantation of a pacemaker (PM) in humans by 
Senning and Elmqvist in 1958, implantable electronic devices have 
evolved into the mainstay of the treatment of cardiac rhythm 
disturbances.1-3 Initially used for management of bradyarrhyth-
mias, these devices have during the last decades been increasingly 
used for treatment of tachyarrythmias as well.4 An implantable PM 
consists of an impulse generator which is typically placed subcuta-
neously in the pectoral region and is connected to endocardium via 
one or two transvenous leads. Powered by a lithium battery, mod-
ern PMs rely on complementary metal oxide semiconductor 
(CMOS) technology, permitting incorporation of up to millions of 
transistors which in turn enable the usage of sophisticated pro-
grammable algorithms in the management of cardiac rhythm dis-
turbances.5 Besides single and dual chamber PMs, cardiac resyn-
chronization therapy PMs (CRT-P) are implanted in selected pa-
tients suffering from systolic dysfunction.6,7 In addition, due to 
treatment modalities such as antitachycardia pacing (ATP) and 
shock therapy, implantable cardioverter defibrillators (ICDs) were 
proven effective in preventing sudden cardiac death in patients at 
risk of life threatening ventricular arrhythmias.8,9 In some devices, 
both defibrillator and resynchronization functions are used concur-
rently [cardiac resynchronization therapy defibrillators (CRT-D)].6 
 With more than 700,000 new PMs and more than 200,000 new 
ICDs implanted worldwide each year, the rate of PM/ICD implanta-
tions is increasing both on a global scale and in Europe.10,11 In 
Denmark, 4,725 PMs were implanted in 2013, of which 3,543 
(75.0%) were first implants.11 The corresponding numbers for ICDs 
were 1,285 and 890 (69.3%), respectively. In addition, 1,001 car-
diac resynchronization therapy (CRT) units were implanted in 
Denmark in 2013.11 
 As the functionality of modern PMs/ICDs to a high extent relies 
on sensing the intrinsic electrical signals of the heart, these devices 
may be susceptible to extraneous signals.12 In order to mitigate 
these effects, the manufacturers have introduced protective 
measures such as shielding in hermetic metal cases, signal filtering, 
interference rejection circuits, modern alternatives to reed switch-
es, and use of bipolar leads.12,13 However, hazardous factors may 
still be present in the medical environment: e.g. electrosurgery, 
direct current external defibrillation, magnetic resonance imaging 
(MRI), neurostimulation, radiofrequency catheter ablation, litho-
tripsy, diagnostic radiation, and cancer radiotherapy (RT).14 As 
interference from these factors may lead to malfunction of the 
cardiac rhythm devices, the ability to predict and reduce these 
negative effects plays a central role for safe treatment of PM/ICD 
patients in these circumstances. 
 This project focuses on external beam RT for cancer in PM/ICD 
patients. Based on three research papers, the present work em-
phasizes the epidemiological, clinical, and safety aspects in the 
management of patients with PM/ICD undergoing RT.
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Background
Due to the ageing and growth of the world population, the burden 
of cancer is increasing.15-17 The number of new cancer cases is 
expected to increase worldwide from 12.7 million in 2008 to 21.4 
million by 2030,18 with lung cancer being the most frequently 
diagnosed cancer type in males and breast cancer in females.16 
Likewise, the incidence of cardiovascular diseases is increasing.19,20 
Being responsible for 31% of deaths worldwide,21 cardiovascular 
diseases are projected to maintain this leading position by 2030.22 
As a result of the age being a risk factor for both cardiovascular 
diseases and cancer, there is a growing probability that some of 
PM/ICD patients will develop malignancies and receive RT treat-
ment. 
 Among cancer treatment options, RT has become an estab-
lished therapy method in oncology, in both curative and palliative 
intent, with at least 50% of all cancer patients requiring RT during 
the course of their illness.23 RT uses high energy radiation to kill or 
damage cancer cells and stop them from growing and multiplying. 
Radiation doses used in cancer therapy are measured in grays (1 
Gy = 1 joule of absorbed energy of ionizing radiation per 1 kg of 
matter). Commonly, RT is given as a course of several treatments 
over days or weeks with daily fractions of typically 1.8-2 Gy. This 
serves two main purposes. Firstly, normal cells are allowed to 
recover between fractions. Secondly, the survived tumor cells may 
have entered a more radiation-sensitive phase of the cell cycle 
before a subsequent fraction. Cumulative doses of curative RT for 
solid tumors generally range from 50 to 80 Gy.24-26 A typical radia-
tion dose for breast cancer is about 50 Gy, while cumulative doses 
of at least 60 Gy are administered for lung cancer.27,28 Lower doses 
of 20-40 Gy may be applied in treatment of lymphomas,29,30 whe-
reas RT for bone metastases usually consists of 8-30 Gy in 1-10 
fractions.31,32 
 At present, the most commonly used types of radiation in RT 
are photons or electrons, which are generated and delivered by a 
RT machine called linear accelerator (LINAC). Along with other 
characteristics, the radiation beams are often described by their 
depth dose curves (Figure 1). By increasing the beam energy of the 
LINAC, the depth of the maximal delivered radiation dose also 
increases. Hence, photons in megavolt (MV) range (commonly 6-20 
MV) are used for more deeply located tumors, whereas electrons 
due to their sharp decline with increasing depth and hence finite 
range are typically used for superficially located tumors. Kilovolt 
(kV) photons are also often used for superficial lesions such as skin 
cancer. 
 RT is normally delivered according to an individually designed 
treatment plan based on image data derived from modalities such 
as computed tomography (CT), MRI, positron emission tomogra-
phy, and ultrasound. When creating this treatment plan, beam 
energy is chosen according to depth of the tumor, also taking other 
parameters such as the number of RT fields and their angles into 
account. 
 
Figure 1: Depth doses for different radiation types and energies. 
 
kV = kilovolt; MeV = megaelectronvolt; MV = megavolt. 
 
Besides injuring the tissues, ionizing radiation may cause damage 
to the circuits in electronic implants. In the early years of treat-
ment with PMs, RT did not pose any considerable threat, as the 
devices from the 1960s and the beginning of the 1970s were based 
on discrete bipolar transistors and were found to be highly resis-
tant to ionizing radiation.33-35 In comparison, modern PMs and ICDs 
rely on CMOS circuitry which has the advantages of greater reliabil-
ity and lower power consumption.36 However, these devices have 
been reported to be more susceptible to malfunctions at exposure 
to ionizing radiation.37 
 Official guidelines for managing PM patients undergoing RT 
were published by The American Association of Physicists in Medi-
cine Task Group No. 34 (AAPM TG-34) in 199438 and give no rec-
ommendations for RT in ICD patients. Furthermore, the recom-
mendations by PM/ICD manufacturers vary regarding both tolera-
ble dose of ionizing radiation and follow-up.39,40 Reimplantation of 
a cardiac device or use of a temporary PM is currently advocated 
before RT if the maximal dose to the PM exceeds 2-10 Gy, while 
removal of the ICD is recommended at even lower radiation doses 
to the device.36,38-41 While these dose levels are lower than the 
cumulative target doses used in cancer treatment, every additional 
surgical intervention to the PM/ICD exposes the patient to a sub-
stantial hazard of infectious and surgical complications42-44 and 
likely augments healthcare costs. Importantly, while some devices 
are able to resist radiation doses considerably higher than recom-
mended as safe,45,46 other PMs/ICDs may malfunction despite 
exposure to only scattered radiation from RT to an anatomically 
remote area.47-51 
 Besides external beam RT, RT is in some cases delivered as 
short range brachytherapy.52 While the literature on the effects of 
this treatment modality on PMs/ICDs is limited, no device malfunc-
tions during brachytherapy have been reported so far.53-55 Mean-
while, although there seems to be no solid evidence that kV pho-
tons should harm modern PMs/ICDs,56 a few prior case reports 
have described PM malfunctions during diagnostic (kV) radiation, 
e.g. in relation to CT.57
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Aims and hypotheses
Aims 
 
Study I 
 To assess the influence of high-energy (18 MV) photon 
beams on modern PMs and ICDs compared to low-
energy (6 MV) photon beams. 
 
Study II 
 To evaluate the effects of cumulative radiation dose and 
beam energy on ICDs in vivo. 
 To determine the feasibility of a porcine model to study the 
effects of ionizing radiation on ICDs. 
 
Study III 
 To quantify the annual rates of RT in patients with PM/ICD. 
 To elucidate safety measures used in clinical practice dur-
ing RT in PM/ICD patients. 
 To quantify the frequency of PM/ICD malfunctions during 
RT. 
 To identify the predictors of PM/ICD malfunctions during 
RT. 
 
Hypotheses 
 Modern PMs/ICDs can resist higher doses of ionizing radia-
tion than generally anticipated (Study I and II). 
 Animal models are feasible for studying the effects of RT on 
ICDs in vivo (Study II). 
 The rate of RT in PM/ICD patients in the general population 
is increasing (Study III). 
 The use of safety measures varies during RT in PM/ICD pa-
tients in clinical practice (Study III). 
 PM/ICD malfunctions can be predicted based on parame-
ters of RT and/or type of the device (Study I and III). 
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Materials and methods
Study I 
The purpose of the study was to evaluate the effects of high-
energy photon beams on modern PMs/ICDs compared to the 
effects of low-energy photon beams in a realistic clinical scenario 
mimicking the actual RT doses used in treatment of a breast can-
cer. 
 
Devices 
Ten unused PMs and two explanted fully functional ICDs were 
exposed to either 6 MV or 18 MV photons (Table 1). 
 
Table 1: Devices irradiated in vitro in Study I. 
6 MV photons 18 MV photons 
Device 
type 
Manufacturer and 
model 
Device 
type 
Manufacturer and 
model 
DDD Biotronik Evia DR-T DDD Biotronik Evia DR-T 
DDD Boston Scientific Altrua 
60 
DDD Boston Scientific 
Altrua 60 
DDD Medtronic Adapta L DDD Medtronic Adapta 
DDD Sorin Esprit DR DDD Sorin Esprit DR 
DDD St. Jude Medical 
Zephyr XL DR 
AAI/VVI St. Jude Medical 
Zephy XL SR 
VVI-ICD Medtronic Secura VR DDD-ICD Medtronic Maximo II 
DR 
AAI = single chamber atrial pacemaker; DDD = dual chamber pacemaker; 
DDD-ICD = dual chamber implantable cardioverter defibrillator; MV = 
megavolt; VVI = single chamber pacemaker with ventricular lead; VVI-ICD = 
single chamber implantable cardioverter defibrillator. 
 
The PMs were programmed with standard settings, e.g. DDDR 60-
130 beats per minute (bpm), output 3.5 V / 0.4 ms on both chan-
nels. Regarding the ICDs, antitachycardia pacing and shock thera-
pies were inactivated. Ventricular tachycardia (VT) monitor zones 
were programmed active, e.g. VT zone from 167 bpm and ventricu-
lar fibrillation (VF) zone from 214 bpm. All lead connector ports 
were closed with pin plugs. 
 
Irradiations 
Each device was irradiated repeatedly with 2 Gy daily for five days 
followed by a two-day break. The photon beams were generated 
by a Clinac iX LINAC (Varian Medical Systems, Inc., Palo Alto, CA, 
USA) and delivered with a dose rate of 600 monitor units/min. 
During irradiations, the devices were placed in a custom manufac-
tured polymethyl methacrylate phantom (Figure 2) placed be-
tween adequate build-up material of solid water boards. This 
permitted locating the PMs/ICDs at the depth of dose maximum 
for each photon energy, as the depth where maximum dose is 
delivered correlates with beam energy and field size. The distance 
from the radiation source to the surface of the phantom including 
build-up material was 100 cm. The irradiation field was 10 cm x 10 
cm for the PMs and 15 cm x 15 cm for the ICDs. RT treatment 
planning software (Eclipse v. 10.0, Varian Medical Systems, Inc., 
Palo Alto, CA, USA) was used to plan the irradiations. 
 
Figure 2: Pacemaker located in the radiotherapy field in a 
polymethyl methacrylate phantom. 
 
 
After reaching a cumulative dose of 70 Gy, the doses per fraction in 
the 6-MV group were increased. They consisted of 10, 10, 20, and 
40 Gy and were delivered during the same day. In the 18-MV 
group, single doses were increased after reaching 50 Gy to 10, 10, 
10, 20, 20, and 30 Gy. After reaching 80 Gy in this group, the inter-
vals between the irradiations were prolonged to a median of 55 
days [inter-quartile range (IQR) 28-75]. The irradiations were cho-
sen not to be performed during the same day in order to avoid 
exposing the investigators to the increased in-room level of in-
duced radioactivity due to secondary neutrons. The intervals be-
tween irradiations were also prolonged due to logistic constraints 
at our institution. In both the 6- and the 18-MV group, cumulative 
radiation doses of 150 Gy per device were delivered. 
 
Interrogations 
The PMs and ICDs were interrogated after every radiation dose 
either on the same or on the following day, using manufacturer-
specific standard telemetry equipment. Presence or absence of the 
following events was recorded: 
 Noise during RT sessions; 
 Spontaneous change in programmed device parameters 
without reset to backup mode; 
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 Reset to backup mode or other error, recoverable using the 
programmer; 
 Error, not recoverable using the programmer; 
 Clinically significant reduction in battery capacity; 
 Inappropriate antitachycardia pacing or delivery of shock 
therapy in the ICDs in spite of deactivation of these func-
tions; 
 Loss of telemetry. 
 When all irradiations were completed, the devices were inter-
rogated at least twice during a period of at least two months. 
 
Study II 
The study was performed as a porcine in vivo experiment of acce-
lerated RT delivered to implanted modern ICDs simulating a worst 
case scenario of a device irradiated directly in the RT field. 
 
Implantation procedures 
Five pigs (1 Göttingen minipig and 4 Danish Landrace pigs), all 
weighing around 40 kg, were implanted with ICD systems in our 
Biomedical Research Laboratory. The reason for switching from 
one pig race to another was purely logistic. 
 Prior to the implantation procedures, the animals were pre-
anesthetized with intramuscular injection of Zoletil. Zoletil is a 
veterinarian medicine consisting of a mixture of two dissociative 
anesthetics (Ketamine 6.25 mg/ml and Tiletamine 6.25 mg/ml), a 
benzodiazepine (Zolazepam 6.25 mg/ml), a synthetic opioid (Bu-
torphanol 1.25 mg/ml), and Xylazin (6.25 mg/ml). 
 The animals were intubated and ventilated with Sevoflurane 1% 
using a Dameca Dream anesthesia machine (Dameca, Rodoevre, 
Denmark). Volume-controlled respiration was used. During sur-
gery, the anesthesia was maintained with intravenous infusion of 
Fentanyl 50 µg/ml at 10 ml/h rate and infusion of Midazolam 5 
mg/ml at 10 ml/h rate. The blood pressure was monitored inva-
sively via femoral artery cannulation. If needed, single doses of 
intravenous Ketamine 50-100 mg (50 mg/ml) as an anesthetic, 
potassium chloride 10 mmol to correct hypokalemia, and Lidocaine 
100 mg (10 mg/ml) for ventricular arrhythmias were administered 
during the anesthesia. Antibiotic prophylaxis consisted of a single 
dose of periprocedural intramuscular Gentamycin 80 mg (40 
mg/ml) and intramuscular Benzylpenicillin 5 millions IU, the latter 
continued q.d. for 3 days. 
 The following ICD generators from five different manufacturers 
were implanted: 
 Biotronik Lumax 540 DR-T, unused; 
 Boston Scientific Energen ICD F141, unused; 
 Medtronic Maximo II CRT-D D284TRK, unused; 
 Sorin Paradym SonR CRT-D 8770, explanted; 
 St. Jude Medical Unify CD3235-40, unused. 
 The Medtronic ICD was implanted in a Göttingen minipig, while 
the remaining devices were implanted in Danish Landrace pigs. 
 Intravenous access for placement of the leads was acquired by 
Seldinger technique through a puncture of the brachiocephalic 
vein. Medtronic Capsurefix Novus 5076 52 cm active fixation leads 
(Medtronic Inc., Minneapolis, MN, USA) were used as right atrium 
leads. St. Jude Medical Durata 7120, 65 cm active fixation leads (St. 
Jude Medical, Inc., St. Paul, MN, USA) were implanted in the right 
ventricular septum in all animals. In the Sorin ICD, left-sided Med-
tronic Attain Ability Plus 4296, 88 cm (Medtronic, Inc., Minneapo-
lis, MN, USA) lead was implanted to a branch in the coronary sinus 
as well. Due to price constraints, the left ventricle connector ports 
in the Medtronic and St. Jude Medical ICDs were left unused and 
were closed with pinplugs. The positions of the leads in the heart 
were verified by fluoroscopy. The generators were fixed and placed 
in a subcutaneous pocket after making an incision on the left side 
of the cranial part of the sternum. Shock therapy was not tested at 
the implantations. 
 In the postoperative period, all animals were housed in the 
laboratory and observed for signs of infection and failure to thrive. 
Intramuscular injections of Ketoprofen 300 mg (150 mg/ml) t.i.d. 
for 3 days were used as a pain killer. 
 
Irradiations 
After an average observation time of 9 days (range 4-18), the ani-
mals were anesthetized with intramuscular injections of Zoletil and 
transported to one of the treatment rooms in our Radiotherapy 
Department. The initial dose of Zoletil was 4-5 ml, supplemented 
with 2 ml as needed during the study. During the transportation 
and the irradiations, the pigs were intubated and ventilated with 
Sevofluran 1% by a portable anesthesia machine Siemens SV 900 
(Siemens AG, Munich, Germany). 
 The animals were positioned in a supine position supported by 
a vac lock bag (Par Scientific A/S, Odense, Denmark) on the accele-
rator couch. A Varian Clinac iX LINAC (Varian Medical Systems, Inc., 
Palo Alto, CA, USA) was used (Figure 3). During the study, the heart 
rhythm was monitored with an ECG monitor visible in the operator 
room. 
 The ICDs were interrogated, and all antitachycardia therapies 
were programmed OFF, while detection was left ON. Two or three 
zones were programmed, e.g. a VT zone between 150 bpm and 
200 bpm, a fast VT zone between 200 bpm and 250 bpm, and a VF 
zone above 250 bpm. 
 RT with 6 MV photons and field dimensions of 15 cm x 15 cm, 
with the ICD generator in the center, was planned with a source-
to-surface distance of 100 cm. The area above the ICD generator 
was covered with 5 mm Superflap build-up material (Mick Radio 
Nuclear Instruments Inc., Mt. Vernon, NY, USA) in order to achieve 
the adequate dose to the ICD. The gantry was rotated to ensure a 
perpendicular direction of the beam toward the ICD generator. 
 Incremental doses of 6 MV photons to the ICD generators were 
delivered: 0.5 Gy, 1.0 Gy, 2.0 Gy, 5.0 Gy, and 10.0 Gy, with a total 
radiation dose of 18.5 Gy. Photon energy was then increased to a 
maximum of 18 MV. The area over the ICD generators was covered 
with additional 10 mm of Superflap build-up material to a total of 
15 mm in order to achieve the adequate dose for the ICDs. Irradia-
tion with correspondingly increasing identical doses to the ICDs 
was performed, thus reaching a cumulative dose of 37.0 Gy in all 
cases. 
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Figure 3: Practical setup during the in vivo irradiations. 
 
ICD = implantable cardioverter defibrillator. 
 
Interrogations 
The ICDs were interrogated after every dose step. Programmed 
parameters were assessed, and battery status, lead impedance, 
sense, and capture threshold were measured. After the irradia-
tions, the shock function of the ICDs was tested. Before this, all 
pigs were treated with extra anesthetics and with Rocuronium, a 
muscle relaxant. The shock function of the ICDs was tested with 
both single- and dual-coil setting. VF was induced by T-wave shock 
or 50 Hz pacing. 
 Upon completion of the shock testing, a new control of the 
devices was performed. Afterwards, the animals were killed with 
an overdose of intravenous Pentobarbital 6 g (300 mg/ml), and the 
ICDs were removed. All ICDs were also interrogated 2, 4, and 17-18 
days later. Time period from the irradiations to last additional 
interrogation ranged from 75 to 402 days. 
 
Study III 
 
Study population 
The Danish National Patient Registry (DNPR) contains information 
on all inpatient hospitalizations at Danish non-psychiatric hospitals 
since 1977 and on all emergency room and hospital outpatient 
specialist clinic visits since 1995.58 Each hospital visit is recorded by 
physicians with one primary diagnosis and one or more secondary 
diagnoses classified according to the International Classification of 
Diseases, 8th edition (ICD-8) until the end of 1993, and ICD-10 
thereafter. The DNPR also includes codes for performed proce-
dures: Danish Hospital Sector Classification System (used since 
2000); Nordic Medico-Statistical Committee (NOMESCO) Classifica-
tion of Surgical Procedures (used in 1996-2000); and procedure 
codes used historically before NOMESCO. 
 We used the DNPR to identify all patients in Western Denmark 
with at least one PM/ICD-related procedure or diagnosis code 
registered from January 1, 1977 to December 31, 2012 (all codes 
are provided in Appendix A) who also had a code for RT (planning 
of RT or external RT) recorded between January 1, 2003 and De-
cember 31, 2012. Patients with RT performed prior to insertion of 
their PM/ICD were excluded. 
 
Radiotherapy data 
Data on RT treatments were collected from RT-planning systems at 
Aalborg University Hospital, Aarhus University Hospital, Herning 
Regional Hospital, and Vejle Hospital. In cases of incomplete data 
in the planning systems, the medical files were reviewed. If 
needed, data from the DNPR were subsequently used to identify 
the start and/or end dates and the number of fractions of RT 
course. 
 Data included information on the hospital where RT was deli-
vered, start date, end date, anatomical region irradiated, cumula-
tive tumor dose, number of fractions, fraction dose (maximal ap-
plied during the RT course), beam type, and beam energy (maximal 
applied during the RT course). The anatomical regions were classi-
fied as: head and neck, thorax, esophagus, abdomen and pelvis, 
spine (thoracic and lumbar), upper extremity, and lower extremity. 
In case two anatomical regions were treated simultaneously, the 
one closest to the PM/ICD generator was recorded. If both photons 
and electrons were applied, the treatment was classified as photon 
RT. 
 
PM/ICD data 
Data on PMs/ICDs were collected from implanting cardiology de-
partments at the following hospitals in Western Denmark: Aalborg 
University Hospital, Aarhus University Hospital, Esbjerg Hospital, 
Haderslev Hospital, Herning Regional Hospital, Kolding Hospital, 
Vejle Hospital, and Viborg Regional Hospital. The data included 
information on device class (PM, CRT-P, ICD, or CRT-D), device type 
[single chamber atrial PM (AAI), single chamber PM with ventricu-
lar lead (VVI), single chamber pacemaker with ventricular lead and 
dual chamber sensing (VDD), dual chamber pacemaker (DDD), CRT-
P, single chamber ICD (VVI-ICD), dual chamber ICD (DDD-ICD), or 
CRT-D], generator manufacturer, model, hospital of implantation, 
and follow-up. 
 
Safety measures 
For each RT course we collected information on potential safety 
measures: evaluations at the PM/ICD clinic including visits before, 
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during, and after RT. Scheduling of supplementary visits up to 
three months after RT was recorded as well. Other recorded safety 
measures were reprogramming of the device before RT, applica-
tion of a magnet to the ICD during RT, use of a temporary PM, and 
surgical relocation of the generator. 
 Complications related to application of a temporary PM or 
relocation of the device occurring during a six-month period were 
also recorded. The following complications were defined as major: 
lead-related re-intervention, local infection requiring re-
intervention, device-related systemic infection/endocarditis, 
pneumohotax requiring drainage, cardiac perforation (without or 
with intervention), pocket revision because of pain, generator-lead 
interface problem with re-intervention, haematoma requiring re-
intervention, deep venous thrombosis, Twiddler’s syndrome, 
wound revision, stroke, acute myocardial infarction (AMI), proce-
dure-related death. Minor complications included haematoma 
without re-intervention, resulting in a prolonged hospital stay, 
hospital re-admission, or additional out-patient visit, wound infec-
tion treated with antibiotics, conservatively treated pneumotho-
rax, and lead dislodgement without re-intervention, as suggested 
by Kirkfeldt et al.59 
 
Outcome 
Information on PM/ICD malfunctions potentially attributable to RT 
was obtained through reviews of cardiology records, including 
PM/ICD follow-up charts. Remote monitoring controls were in-
cluded if documented in the patient file. The follow-up period 
ended at first PM/ICD evaluation after completion of RT course or 
on December 31, 2013, whichever came first. 
 PM/ICD malfunctions were categorized as: 
 Electrical reset to backup mode or other minor software 
error; 
 Electrical reset or other software error requiring repro-
gramming of the device by the manufacturer; 
 Unexpected decrease in battery capacity without reaching 
elective replacement indicator (ERI); 
 Unexpected ERI; 
 Loss of telemetry; 
 Change in one or several lead parameters eventually result-
ing in supplementary visits or lead replacement (only the 
changes suspected at the subsequent device control to 
have occurred due to RT and not explained by other va-
riables, such as changes in antiarrhythmic drugs, were 
recorded); 
 Noise oversense without symptomatic pacing inhibition, 
ATP, or shock therapy; 
 Oversense with symptomatic pacing inhibition, ATP, or 
shock therapy. 
 
Statistical analyses 
 
Study I 
Using the cumulative dose of ionizing radiation as a substitute for 
time scale, an equivalent of survival analysis was performed until 
first potentially clinically hazardous failure for every device. 
 The data were interval censored as the exact radiation dose at 
the exact time malfunction occurred was unknown. To accommo-
date for this, the events were placed either at the starting-point of 
the interval, at the mid-point, or at the end-point of the interval. 
Kaplan-Meier curves were plotted to illustrate this approach. Using 
a Cox proportional hazard regression model, the mid-points were 
compared. In the same manner, start-point events in the 6-MV 
group were compared to end-point events in the 18-MV group, 
and reversely. Due to the low number of events, p-values do not 
have any practical interpretation and confidence intervals (CIs) 
may not have 95% coverage. Hence we refrain from reporting p-
values, and emphasize that caution should be taken when inter-
preting CIs.  
 The incidence rate of all potentially hazardous malfunctions 
was compared between the two groups with regard of the cumula-
tive dose. To accommodate for correlation within pacemakers a 
population averaged repeated measures logistic regression model 
was applied to detect potential differences between groups.60 This 
requires a balanced design between groups. The dose per faction 
were not the same for the two groups, hence a balanced design 
was achieved by collapsing non-overlapping intervals. 
 
Study II 
In this descriptive explorative study, continuous variables were 
expressed as absolute values or means. Changes in PM/ICD battery 
voltages were analyzed by linear regression. 
 
Study III 
Continuous variables were reported as medians and IQRs. Categor-
ical variables were expressed as counts and percentages. Conti-
nuous variables were compared by Wilcoxon rank sum test. The 
annual rate of RT in PM/ICD patients was calculated by using the 
total Western Denmark population (obtained from Statistics Den-
mark). 
 The device malfunctions and safety measures were compared 
at RT treatment course (consisting of one or more fractions) level. 
Only RT courses with a later device control were included in the 
analysis of the malfunctions. 
 Odds ratios (ORs) with 95% CIs of PM/ICD malfunctions were 
computed using logistic regression. Independent variables in the 
model were type of device (ICD vs. PM), anatomical region irra-
diated (below vs. above the diaphragm), cumulative radiation dose 
to the tumor (10 Gy increments), fraction dose (1 Gy increments), 
and beam energy (≥15 MV vs. <15 MV). The cut-off value of 15 MV 
for beam energy was chosen entirely based on sensitivity and 
specificity, since this value gave a high sensitivity to detect device 
malfunctions (79%) and a higher specificity (61%) than other values 
with equally high sensitivity. Adjusted ORs were adjusted for beam 
energy. 
 As some patients received more than one RT course, the RT 
courses were not completely independent. To accommodate for 
this dependence, the method of generalized estimating equations 
was used in a generalized linear model.61 
 Statistical analyses were performed using Stata versions IC 11.2 
and 13.1 (StataCorp LP, College Station, TX, USA). 
 
Ethics 
Prior to the experiments in Study II, a written permission to con-
duct the study was obtained from the Danish Animal Experiments 
Inspectorate (permission number 2011/561-59). Study III was 
approved by the Danish Health and Medicines Authority (record 
number 3-3013-300/1) and the Danish Data Protection Agency 
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(record number 2008-58-0028) allowing the researchers to access registry data and to review medical records of the study patients.
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Results
Study I 
Detected PM and ICD malfunctions are summarized in Table 2. In 
the 6-MV group, no malfunctions were detected in Biotronik, 
Boston Scientific, St. Jude Medical, or Sorin PMs. The Medtronic 
PM suddenly lost telemetry capability after reaching a cumulative 
dose of 150 Gy. The telemetry capabilities were neither present 6 
nor 29 days later. However, the device was able to communicate at 
a supplementary interrogation 269 days after the last irradiation. 
The PM reported an electrical reset 81 days after last RT. 
 At interrogations, all devices from Medtronic reported multiple 
ventricular high-rate episodes (VHRs). These episodes usually 
lasted a few seconds and were not related in time to RT. 
 In the 18-MV group, the Medtronic ICD lost its preprogrammed 
patient data after reaching 44 Gy. No other malfunctions in this 
device were recorded, except for the above mentioned susceptibil-
ity to report artifacts as VHRs. All PMs in the 18-MV group exhi-
bited some degree of potentially hazardous failure. The most 
common abnormal behavior was electrical reset, which is a fallback 
to backup or “safe” mode. The PMs could be reprogrammed to 
initial settings by using automatic algorithms in the programmers 
except the St. Jude Medical PM (after 150 Gy). In the Medtronic 
PM, battery depletion was present after reaching 150 Gy. All de-
vices in the 18-MV group preserved their telemetry capabilities. No 
inappropriate ATP or shock therapy was reported by the ICDs. 
 Figure 4 shows the radiation dose given before first malfunc-
tion. The Cox-regression analysis comparing the assumption of 
events occurring at the mid-point in both groups showed a hazard 
ratio (HR) of 9.11 (approximate 95% CI: 1.04-79.69). Comparison of 
events occurring at the start-point of intervals in the 6-MV group 
to end-point in the 18-MV group yielded the same HR and CI, as 
events occurred in the same order. Assuming that events occur at 
the end-point in 6-MV and at the start-point in the 18-MV yielded a 
HR of 11.32 (approximate 95% CI: 1.24-103.55). 
 
Table 2: Recorded pacemaker and ICD malfunctions during the 
irradiations. A cumulative dose of 150 Gy was reached in all 
devices. 
Device Malfunctions in the 6-
MV group 
Malfunctions in the 18-MV 
group 
Biotronik PM None Reset after 100, 120, and 150 
Gy 
Boston 
Scientific PM 
None Reset after 30 Gy 
Medtronic PM No telemetry after 
150 Gy 
RRT/ERI detected after 150 Gy 
Sorin PM None Reset after 80, 120, and 150 
Gy 
St. Jude 
Medical PM 
None Reset after 32, 42, 80, 100, 
and 120 Gy 
Error after 150 Gy 
Medtronic ICD None None, except for loss of 
patient data after 44 Gy 
ERI = elective replacement indicator; Gy = gray; ICD = implantable 
cardioverter defibrillator; MV = megavolt; PM = pacemaker; RRT = 
recommended replacement time. 
 
Figure 4: Kaplan-Meier graph of dose to first malfunction. 
 
Typical therapeutic doses are marked on the dose axis. Gy = gray; MV = 
megavolt. 
 
The incidence rates of all episodes of potentially hazardous mal-
functions in the two groups in regard to cumulative dose were 
compared by repeated measures logistic regression. The 18-MV 
group showed an increased risk of malfunction with an OR of 18.29 
(approximate 95% CI: 1.52-219.41). 
 
Study II 
The animals tolerated the implantation procedures, transporta-
tions, and irradiations well. No significant hemodynamic distur-
bances or infectious complications were present. 
 During all irradiations, the animals maintained sinus rhythm 
without any arrhythmias on the monitor. Programmed settings in 
all the ICDs remained stable between the fractions. During the 
irradiations, the devices reported no stored arrhythmias, noise, or 
oversense events. No reset, other unexpected behavior, or mal-
function in the ICDs was observed during the irradiations. The ICDs 
detected VF correctly and delivered therapy as programmed in all 
tests. Defibrillator threshold in dual coil and active can configura-
tion ranged from 10.4 to 41 J, and from 10 to 41 J in single coil and 
active can. 
 In the Medtronic ICD, a temporary decrease in battery voltage 
by 0.16 V or 5.2% was observed starting at a cumulative dose of 
18.5 Gy. This decline was statistically significant by linear regres-
sion analysis, with 0.018 V between interrogations (p=0.028). 
Battery voltage at interrogations 2, 4, and 18 days after the irradia-
tions was 2.97 V, 2.98 V, and 3.06 V, respectively, thus returned to 
the initial value. 
 In the Sorin ICD, the magnet rate had decreased from 91 to 85 
bpm at interrogation 2 days after the irradiations. At the same 
time, the battery voltage decreased from 3.0 to 2.9 V. These para-
meters increased gradually and reached 89 bpm and 3.0 V, respec-
tively, at day 26. 
 The Biotronik ICD experienced a fallback to a back-up mode at 
00:01 the night after the irradiations. The device had thus reverted 
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to a safe program: pace mode VVI 70 bpm, output 7,5 V / 1.5 ms, 
VF zone from 150 bpm (400 ms), maximum energy shock of 40 J. 
The ICD could not be reprogrammed using a clinical interface in the 
programmer, and a firmware update of the ICD had to be per-
formed by the manufacturer. Afterwards, no malfunction was 
detected at controls up to 75 days from the irradiations. 
 Compared with data at the day 2 control, the Boston Scientific 
ICD showed an increase in power consumption and a decrease in 
remaining battery charge at the interrogation 4 days after the 
irradiations. The power consumption increased from 31 to 40 µW, 
and the remaining battery charge decreased from 1.70 to 1.67 Ah. 
The parameters were at 31 µW and 1.67 V at the day 17 interroga-
tion and remained stable. 
 During the study, all lead parameters, including impedance, 
sense, and capture threshold, remained stable. 
 
Study III 
 
Descriptive characteristics 
Among 690 PM/ICD patients recorded in the DNPR, we included 
560 (81.2%) patients with 678 separate RT courses in the study 
(Figure 5). Among the 130 excluded patients, 79 (60.8%) only had a 
temporary PM before RT, while the remaining 51 (39.2%) were 
excluded due to not receiving RT, not having a PM/ICD at all, 
PM/ICD not being implanted until RT, only having a loop recorder, 
or RT being started after 2012. 
 The annual rate of RT courses in PM/ICD patients increased by 
199% from 1.45 to 4.33 per 100,000 person-years from 2003 to 
2012 (Figure 6). 
 The median age at start of RT (first RT in case of several RT 
courses) was 75.6 years (IQR 69.3-81.7 years), with predominance 
of males (68.4%). Most patients had only one device during the 
study period. Six patients (1.1%) had two devices (Table 3). 
 Bradycardia PMs constituted the majority of the devices [462 
(82.5%)] of which dual chamber models were dominant [331 
(59.1%) of 560 devices]. There were 25 (4.5%) CRT-Ps. Defibrilla-
tors, including ICDs [54 (9.6%)] and CRT-Ds [19 (3.4%)], 
represented 73 (13.0%) of the devices. 
 Among the 678 separate RT courses, complete data on both the 
device and RT were available in 658 (97.1%), of which 453 (68.8%) 
had at least one subsequent PM/ICD control. One-year mortality 
among patients with complete data on last RT course, but no de-
vice control afterwards, (n=185) was 93.5% compared with 28.2% 
among those who had a device control (n=358). In the RT courses 
with subsequent control, patients tended to be younger and were 
more often treated with kV photons or electrons, while tumor 
dose, beam energy, proportion of ICDs, as well as frequency of RT 
to thorax were higher compared with RT courses without control. 
 The most common anatomical region was thorax (36.0%) fol-
lowed by head and neck (27.2%), and abdomen and pelvis (27.1%). 
The remaining 9.7% regions were spine, extremities, and esopha-
gus. Median time from device implantation to start of RT was 2.7 
years (IQR 1.0-5.0). 
 The PMs/ICDs were manufactured by 13 companies, with Med-
tronic most frequently represented [227 (40.1%) of 556 devices 
with known manufacturer], followed by St. Jude Medical [175 
(30.9%)] (Appendix B). 
 
Figure 5: Flowchart of the study population in Study III. 
 
ICD = implantable cardioverter defibrillator; PM = pacemaker; RT = 
radiotherapy. 
 
Figure 6: Annual rates of radiotherapy courses in patients with 
pacemakers or implantable cardioverter defibrillators in Western 
Denmark, 2003-2012. 
 
ICD =implantable cardioverter defibrillator; RT = radiotherapy. 
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Table 3: Baseline characteristics of 560 patients with pacemaker 
or implantable cardioverter defibrillator receiving radiotherapy, 
2003-2012. 
Variable  
Age, years*† 75.6 (69.3-81.7) 
Male, n (%) 383 (68.4) 
Female, n (%) 177 (31.6) 
Number of RT courses per patient* 1 (1-1) 
1, n (%) 470 (83.9) 
2, n (%) 73 (13.0) 
3, n (%) 13 (2.3) 
4, n (%) 2 (0.4) 
5, n (%) 1 (0.2) 
10, n (%) 1 (0.2) 
Age of the device at RT, years*† 2.6 (0.9-4.8) 
Device class†  
Single chamber PM, n (%) 130 (23.2) 
Dual chamber PM, n (%) 331 (59.1) 
PM, unspecified, n (%) 1 (0.2) 
CRT-P, n (%) 25 (4.5) 
ICD (single and dual chamber), n (%) 54 (9.6) 
CRT-D, n (%) 19 (3.4) 
CRT-D = cardiac resynchronization therapy defibrillator; CRT-P = cardiac 
resynchronization therapy pacemaker; ICD = implantable cardioverter 
defibrillator; PM = pacemaker; RT = radiotherapy. *Values are shown as 
median (interquartile range). †During first RT course with the first device in 
case of several RT courses and/or several devices in the patient. 
 
Safety measures 
Precautionary device relocation from the RT field was performed in 
24 (3.5%) of 678 RT courses. In these cases, the same generator 
was reused in two (8.3%) patients. At least one lead was extracted 
in eight (33.3%), and at least one new lead was implanted in 20 
(83.3%) procedures. Among RT courses to thorax with complete 
data (n=237), in cases where the device was relocated, both the 
cumulative radiation dose and the beam energy were higher com-
pared with RT courses without PM/ICD relocation [46.5 Gy (IQR 
22.5-48 Gy) and 20 Gy (IQR 10-30 Gy), respectively, p=0.0001, and 
15 MV (IQR 9-18 MV) and 6 MV (IQR 6-15 MV), respectively, 
p=0.0011]. One of the patients suffered a major complication after 
device relocation (AMI). In terms of minor complications, the same 
patient had a displacement of the atrial lead without intervention. 
Another patient experienced a hematoma in the pacemaker pocket 
resulting in additional clinic visits. No backup temporary PM was 
used for any of the RTs. 
 Data on scheduling visits at PM clinics specifically due to up-
coming RT was available for 655 RT courses in 549 patients. In 101 
(15.4%) of these RT courses, the patient was seen both before and 
upon completion of the RT course, while 47 (7.2%) patients were 
only controlled before RT and 82 (12.5%) only had a control after 
completion. Thus, device controls due to RT before and after the 
RT course were performed in 148 (22.6%) and 183 (27.9%) RT 
courses, respectively. Among 533 RT courses consisting of more 
than one fraction, device control was performed at least once 
during the RT course in 76 (14.3%) of RT courses. A supplementary 
control within three months after RT was performed in 26 (4.0%) 
RT courses. The proportion of RT courses leading to device controls 
was highest among RT courses with photons in MV range, followed 
by electrons and kV photons (Figure 7). The median time from last 
RT fraction to first device control was 31 days (IQR 2-145 days) in 
453 RT courses with a subsequent control. In 205 (31.2%) RT 
courses the device was never controlled after the RT (Figure 5). 
 The proportion of RT courses leading to a subsequent device 
evaluation was higher when the tumor was located above the 
diaphragm and in cases where higher beam energy was used 
(Figure 8). Hence, at <15 MV, the patients were scheduled for a 
device evaluation after 26.2% of RT courses given above the diaph-
ragm and in 12.9% of those under the diaphragm (24.2% in total at 
<15 MV). At ≥15 MV, the proportions were 42.0% and 29.1%, 
respectively (34.4% in total at ≥15 MV). 
 
Figure 7: Proportions of radiotherapy courses with device 
controls scheduled due to radiotherapy, classified by beam 
type. 
 
kV = kilovolt; MV = megavolt; RT = radiotherapy. *At least one control in 
radiotherapy courses consisting of >1 fraction. 
 
Figure 8: Percentages of radiotherapy courses with a 
subsequently scheduled device evaluation, by the anatomical 
localization of the tumor and beam energy. 
 
MV = megavolt. 
 
Application of a magnet to the ICD during irradiations after cardi-
ologists recommendation was used in 8 (10.8%) of 74 treatments 
with implanted ICD in treatments with available data on safety 
measures. Reprogramming of the device prior to RT was only do-
cumented in nine PMs and one ICD (1.5% of 655 RT courses), and it 
mainly consisted of increasing pacing output and/or reprogram-
ming to fixed-mode pacing. In the ICD, the antitachycardia thera-
pies were inactivated during the RT sessions. 
 
Device malfunctions 
Among 453 RT courses with complete data on devices and RT and a 
device control after RT, 14 (3.1%) device malfunctions occurred 
(Table 4). 
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Table 4: Characteristics of radiotherapy (RT) courses resulting in device malfunction versus RT courses without malfunction, 
compared with RT courses without later device control, including RT courses with complete data on both the device and the RT (n = 
658). 
 PM/ICD controlled after RT PM/ICD never controlled 
after RT‡ PM/ICD 
malfunction† 
No PM/ICD 
malfunction† 
Total‡ 
N (%) 14 (3.1) 439 (96.9) 453 205 
Age, years* 72.5 (68.4-77.8) 75.0 (68.9-80.3) 74.7 (68.9-80.3) 77.6 (70.6-82.7) 
Device class     
PM: all classes, n (%) 10 (2.5) 384 (97.5) 394 (87.0) 188 (91.7) 
Single chamber PM, n (%) 1 (1.1) 93 (98.9) 94 (20.8) 55 (26.8) 
Dual chamber PM, n (%) 9 (3.3) 267 (96.7) 276 (60.9) 125 (61.0) 
CRT-P, n (%) 0 (0.0) 24 (100.0) 24 (5.3) 8 (3.9) 
ICD: all classes, n (%) 4 (6.8) 55 (93.2) 59 (13.0) 17 (8.3) 
ICD (single and dual chamber), n (%) 2 (4.2) 46 (95.8) 48 (10.6) 11 (5.4) 
CRT-D, n (%) 2 (18.2) 9 (81.8) 11 (2.4) 6 (2.9) 
Anatomical region     
Head and neck, n (%) 1 (0.8) 118 (99.2) 119 (26.3) 60 (29.3) 
Thorax, n (%) 4 (2.2) 174 (97.8) 178 (39.3) 59 (28.8) 
Esophagus, n (%) 0 (0.0) 3 (100.0) 3 (0.7) 2 (1.0) 
Abdomen and pelvis, n (%) 7 (5.6) 118 (94.4) 125 (27.6) 53 (25.9) 
Spine, n (%) 1 (5.9) 16 (94.1) 17 (3.8) 20 (9.8) 
Upper extremity, n (%) 0 (0.0) 3 (100.0) 3 (0.7) 4 (2.0) 
Lower extremity, n (%) 1 (12.5) 7 (87.5) 8 (1.8) 7 (3.4) 
Cumulative tumor dose, Gy* 46.5 (20-70) 30 (20-52) 30 (20-52) 20 (20-25) 
Number of fractions* 24 (4-35) 9 (4-24) 9 (4-24) 4 (3-5) 
Fraction dose, Gy* 2 (2-5) 5 (2-5) 5 (2-5) 5 (5-5) 
Beam type     
Photons, n (%) 14 (3.6) 371 (96.4) 385 (85.0) 191 (93.2) 
Photons in MV range, n (%) 14 (4.0) 339 (96.0) 353 (77.9) 185 (90.2) 
Photons in kV range, n (%) 0 (0.0) 32 (100.0) 32 (7.1) 6 (2.9) 
Electrons, n (%) 0 (0.0) 68 (100.0) 68 (15.0) 14 (6.8) 
Beam energy, MV* 16.5 (15-18) 8 (6-15) 9 (6-15) 6 (6-15) 
Time from last RT fraction to following first PM/ICD 
control, days* 
1.5 (0-15) 34 (3-158) 31 (2-145) - 
Device age at RT, years* 2.4 (0.6-5.5) 2.8 (1.0-5.0) 2.8 (1.0-5.0) 2.6 (1.0-4.7) 
CRT-D = cardiac resynchronization therapy implantable cardioverter defibrillator; CRT-P = cardiac resynchronization therapy pacemaker; Gy = gray; ICD = 
implantable cardioverter defibrillator; IQR = interquartile range; MV = megavolt; PM = pacemaker; RT = radiotherapy. *Values are shown as median 
(interquartile range). †Percentages are row percentages to allow for comparison of RT courses with and without device malfunctions. ‡Percentages are 
column percentages to allow for comparison of RT courses with and without later device control. 
 
The median cumulative radiation dose in RT courses associated 
with device malfunctions was 46.5 Gy (IQR 20-70 Gy), and the 
median beam energy was 16.5 MV (IQR 15-18 MV) compared with 
30 Gy (IQR 20-52 Gy) and 8 MV (IQR 6-15 MV) in treatments with-
out malfunctions. No PM/ICD malfunctions were observed during 
electron RT or photon RT in kV range. 
 Seven (50%) malfunctions occurred during RT for tumors lo-
cated in abdomen or pelvis while 4 (28.6%) involved RT of the 
thorax (Appendix C). The most frequent malfunction was electrical 
reset or transient minor software errors, occurring in 11 (78.6%) of 
affected devices. In these cases, the device could be repro-
grammed by the staff in the clinic, whereas in 2 (14.3%) cases, 
assistance from the manufacturer was necessary in order to up-
date the software of the device. In one PM, the only deviation was 
an increase in atrial pacing threshold from 1.25V to 2.75V. Impor-
tantly, no malfunctions required device explantation or lead revi-
sion. In terms of other adverse clinical consequences from the 
malfunctions, one patient experienced diaphragmatic pacing after 
the reset of a single-chamber PM which ceased after reprogram-
ming of the device. 
 
Predictors of device malfunctions 
Crude logistic regression analysis showed that PM/ICD malfunc-
tions were associated with beam energy ≥15 MV (OR 5.73, 95% CI 
1.58-20.76) and location of the tumor below the diaphragm (OR 
4.31, 95% CI 1.42-13.12) (Table 5). 
 
Table 5: Crude and adjusted logistic regression analysis of 
factors associated with PM/ICD malfunctions during 
radiotherapy courses (n=453). 
Variable Crude OR (95% CI) Adjusted OR (95% CI) 
Device class: ICD, CRT-D 
vs. PM, CRT-P 
2.78 (0.84-9.15) 2.93 (0.87-9.86) 
Anatomical location of 
the tumor: below 
diaphragm vs. above 
diaphragm 
4.31 (1.42-13.12) 2.27 (0.65-7.95) 
Cumulative tumor dose 
(10 Gy increment) 
1.20 (0.95-1.52) 1.13 (0.89-1.44) 
Fraction dose (1 Gy 
increment) 
0.83 (0.64-1.08) 0.92 (0.71-1.18) 
Beam energy (≥15 MV vs. 
<15 MV) 
5.73 (1.58-20.76) 1.0 (reference) 
CI = confidence interval; CRT-D = cardiac resynchronization therapy defibril-
lator; CRT-P = cardiac resynchronisation therapy pacemaker; Gy = gray; ICD 
=implantable cardioverter defibrillator; MV = megavolt; OR = odds ratio; 
PM = pacemaker. 
 
The median beam energy used for treatment of tumors located 
above diaphragm (6 MV, IQR 6-10 MV) was lower than the median 
beam energy used below diaphragm (15 MV, IQR 15-18 MV). After 
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adjustment for beam energy, the latter remained the only signifi-
cant predictor of device malfunction. 
 Interestingly, no significant correlation was detected between 
device malfunctions and cumulative radiation dose to the tumor 
(adjusted OR 1.13, 95% CI 0.89-1.44) or fraction dose (adjusted OR 
0.92, 95% CI 0.71-1.18). Although insignificant, device malfunctions 
were more frequent in ICDs (6.8%) compared with PMs (2.5%), 
adjusted OR 2.93, 95% CI 0.87-9.86.
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Discussion
Prevalence of patients with PM/ICD 
undergoing RT 
To date, no large-scale studies on the size of the population of 
PM/ICD patients undergoing RT have been performed. In 1991, 
Rodriguez et al. estimated, based on clinical experience, that 0.4-
0.5% patients undergoing RT had a PM/ICD.62 In 2000, Tsekos et al. 
reported that they saw at least 10 PM patients per year at their RT 
department at a university hospital.63 In 2004, Solan et al. also 
stated that any busy RT department would see several PM/ICD 
patients per year.39 More recently, Gossman et al. estimated, 
based on survey data, that the median proportion of RT patients 
requiring a change in the RT approach due to PM/ICD was 0.8%, 
and expected the total proportion of RT patients having a PM/ICD 
to be higher.64 In the present study, the annual rate of RT courses 
in Western Denmark reached 4.33 per 100,000 person-years in 
2012. Our findings also demonstrate a sharp increase in the annual 
rate by 199% during the ten-year period from 2003 to 2012. 
 
Probability and consequences of device 
malfunction 
Since the publication of the AAPM TG-34 guidelines,38 numerous in 
vitro experiments on the effects of RT on both PMs and ICDs have 
been reported (Table 6 and Table 7). 
 Variations exist in the reported rates of device malfunctions. 
Differences are also present in terms of radiation doses at these 
episodes. Hurkmans et al. irradiated 19 PMs with 6 MV photons to 
a dose of up to 120-130 Gy.65 Points of first malfunctions varied 
from 10 to 120 Gy, while five devices were irradiated with full dose 
without any adverse effects. In the largest in vitro study so far, 
Mouton et al. analyzed the effects of direct irradiation with 18 MV 
photons on 96 PMs, reaching doses up to 200 Gy per device.66 The 
authors classified the observed malfunctions, with three of the 
classes being potentially lethal: amplitude change of >10%, pauses 
in electrical signal of >10s, and permanent silence. These malfunc-
tions were observed at doses starting from 2 Gy, 0.15 Gy, and 0.5 
Gy, with mean doses at their occurrence of 56 Gy, 17.4 Gy, and 71 
Gy, respectively. The majority (70%) of malfunctions were ob-
served at a dose rate of 8 Gy/min, with no malfunctions occurring 
at or below the dose rate of 0.2 Gy/min, thus suggesting that dose 
rate is a potential risk factor in inducing PM/ICD malfunctions. 
 In terms of in vitro studies on ICDs, Hurkmans et al. exposed 11 
ICDs to 6 MV photons, reaching a dose of 120 Gy.67 Failures were 
observed in all devices with doses at first malfunction varying from 
0.5 Gy to 120 Gy. Of note, sensing interference was observed in all 
these devices, potentially leading to shock therapy in case of a 
clinical situation. At the same time, exposing 20 ICDs (including 8 
CRT-Ds) to 4 Gy of scattered radiation from a 6 MV photon beam, 
Kapa et al. reported no device malfunctions.68 Hashii et al. com-
pared the effects of different beam energies on four ICDs from one 
manufacturer in vitro.69 An accelerated course of RT was imitated 
with the ICDs outside the RT field. Interrogating the devices every 
10–50 Gy, the authors found that scattered radiation with 18 MV 
photons led to a greater number of software errors, compared 
with 10 MV. In addition, dosimetry showed that during high-energy 
beaming, more neutrons are generated. The authors expressed 
their concern regarding the risk of ICD malfunction during high-
energy photon irradiations even with devices located at a distance 
from the RT field. 
 Along with in vitro experiments, a number of case reports and 
case series have been published as well (Table 8 and Table 9). 
 In terms of malfunction rate, the proportion of 3.1% in Study III 
is in line with a retrospective study by Gossman et al., who re-
ported device malfunctions in four (3.6%) out of 112 RT courses in 
PM/ICD patients.64 With a median time from RT to the first device 
control of 31 days in 453 devices, the follow-up period in Study III 
corresponds to 14043 device-days, suggesting approximately 1 
malfunction per 1000 device-days. Hence, this rate seems to be 
higher than the rate of spontaneous minor software errors of 
approximately 1 event per 13000 device-days, as observed by 
Bradley and Normand in ICDs.70 The rate of device malfunctions in 
Study III might even have been higher, since 24 devices were relo-
cated before the RT. The proportion of device malfunctions is 
comparable with the findings by Makkar et al. who observed two 
partial resets of ICDs, exposed to 1.23 Gy and 0.04 Gy, respectively, 
(2.9% of all devices) among 69 patients [50 (72.5%) PMs, 19 
ICDs].50 The remaining intact devices received doses ranging from 
0.9 to 5.057 Gy with 6-16 MV photons with or without electrons. In 
a study of 62 patients [60 (96.8%) PMs, 2 ICDs], Soejima et al. 
observed one PM (1.6% of all devices) that reset during RT for 
prostate cancer with 15 MV photons.49 The remaining 61 devices 
were exposed to radiation doses reaching as high as 20.7 Gy (>2 Gy 
in six cases), thus indicating that PMs/ICDs may develop malfunc-
tions outside the RT beam and the occurrence of malfunctions may 
not be related to radiation dose. 
 Regarding proton beam RT, Oshiro et al. observed malfunctions 
in two (25%) out of eight PM patients with devices located outside 
the RT field.71 In a study of 42 patients (28 PMs, 14 ICDs) under-
going proton RT with varying doses to the device, Gomez et al. 
observed five resets during thoracic RT in four (9.5%) patients and 
an expected ERI in one patient.72 Hence, these limited clinical data 
suggest that probability of PM/ICD malfunction during proton RT 
might be higher compared with photon RT. However, with only five 
devices described in an in vitro setting of proton RT,71,73 probably 
no direct firm conclusions can be drawn to support this statement. 
Clinical data on neutron beam RT in PM/ICD patients are even 
scarcer. To the best of our knowledge, there has only been pub-
lished one case report on uncontrollable pacing occurring during 
neutron RT to thyroid.74 Although limited to 16 PMs, in vitro data 
suggest that PMs/ICDs might be even more sensitive to neutron RT 
compared with other beam types.75,76 
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Table 6: Studies examining the effects of radiotherapy on pacemakers in vitro, published in English since 1994. 
Year Author n Beam type Beam energy, 
MV 
Maximal 
generator 
dose, Gy 
Main results 
1994 Souliman77 18 Photons 8 70 Complete failure at 16.8-70 Gy in 11 PMs. No effects from EMI alone. 
1999 Mouton78 42 Photons 
(n=19); Co-60 
(n=23) 
4 (LINAC); 
1.17-1.33 (Co-
60 source) 
140 No malfunction at therapeutic doses (n=15); frequency modifications 
(n=9) starting at 2 Gy; deprogramming and modification in battery 
characteristics (n=11) starting at 4 Gy; destruction of the PM (n=7) at 
44-77 Gy. 
2002 Mouton66 96 Photons 18 200 Amplitude change >10%: 38 PMs at 2-130 Gy; silence >10 s: 35 PMs 
at 0.15-74 Gy; permanent silence: 12 PMs at 0.5-170 Gy. 
2005 Hurkmans65 19 Photons 6 120; 130 (n=2) 5 PMs: no malfunction; 7 PMs: no output at 80-130 Gy; 5 PMs: ERI at 
120-130 Gy; 2 PMs: no communication at 20-130 Gy; 8 PMs: 
inhibition during direct irradiations. 
2008 Oshiro71 1 Protons 250 NA (35 Gy to 
the lead) 
No malfunctions. 
2011 Koivunoro75 2 Epithermal 
neutrons 
0.414 eV < E < 
9.12 keV 
1.2; 2.0 Reset due to memory changes in microprocessor; many severe bit 
flips and loss of telemetry. Both PMs got activated. 
2012 Trigano76 14 Neutrons 3-50 (peak 
around 20) 
NA Electrical reset in 6 cases. 
2014 Zaremba79 
(Study I) 
10 Photons 6; 18 150 6 MV group: one episode of malfunction at 150 Gy; 18 MV group: 14 
episodes of malfunction starting at 30 Gy. 
Co = cobalt; E = energy; EMI = electromagnetic interference; ERI = elective replacement indicator; eV = electronvolt; Gy = gray; LINAC = linear accelerator; 
MV = megavolt; PM = pacemaker. 
 
Table 7: Studies examining the effects of radiotherapy on implantable cardioverter defibrilators in vitro, published in English since 
1994. 
Year Author n Beam 
type 
Beam 
energy 
Dose, Gy Main results 
2002 Hoecht80 5 NA NA Scatter; 
>50 
No effects from EMI; scatter radiation: 1 fallback; direct exposure: 
malfunctions at >50 Gy, unspecified. 
2005 Hurkmans67 11 Photons 6 120 Sensing interference in all ICDs, which would have resulted in shock in 4 ICDs. 
Failure of all devices at 0.5-120 Gy. Complete loss of function at 0.5-1.5 Gy in 4 
ICDs. 
2008 Kapa68 20 (8 of 
them CRT-
D) 
Photons 6 4 No malfunctions. 
2012 Hashimoto73 4 Protons 200 Scatter 1 power-on reset per approximately 50 Gy, 1 soft error per approximately 15 
Gy. No permanent malfunctions. 
2013 Hashii69 10 Photons 10; 18 Scatter More soft errors during irradiation with 18 MV photons compared with 10 MV 
photons. No hard errors or permanent malfunctions. 
2014 Mollerus81 8 Photons 6 131.11 4 contemporary devices remained functional after 131.11 Gy despite minor 
memory faults in 3 of them; 4 legacy devices failed to deliver shock therapy 
after 41.11 Gy and had changes in lead impedance. 
2014 Zaremba79 
(Study I) 
2 Photons 6; 18 150 6 MV: no malfunctions; 18 MV: no malfunctions, except loss of patient data 
after 44 Gy. 
CRT-D = cardiac resynchronization therapy defibrillator; EMI = electromagnetic interference; Gy = gray; ICD = implantable cardioverter defibrillator; MV = 
megavolt. 
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 Concerning severity and clinical consequences of RT-induced 
PM/ICD malfunctions, removal of the device due to malfunction 
has been described in five published cases (two PMs, three ICDs) 
over the last two decades.74,80,82-84 Of note, the generators were 
located outside the direct RT field in all of these patients, and no 
lethal malfunctions have been reported. In a number of other 
published PM/ICD malfunction cases, the devices were either 
successfully reprogrammed, or the effects were transient, permit-
ting completion of the RT.47-51,63,71,72,85 Similarly, no patients in 
Study III required device explantation, and the majority of the 
observed malfunctions were resets or transient software errors. In 
Study I, ERI was first recorded after 150 Gy in two devices, i.e. at 
supratherapeutic doses. In Study II, one episode of reset was ob-
served, after which the device could be reprogrammed. Mean-
while, despite the fact that a PM/ICD after undergoing a reset is 
capable of delivering a basic treatment to the patient, it may be 
inappropriate for the patient to have the device functioning in this 
mode for a longer period due to deprivation of atrioventricular 
synchrony, rate-adaptive pacing, or biventricular pacing.86-88 In 
addition, one of the patients in Study III experienced diaphragmatic 
pacing. Regarding PM-dependent patients, while permanent or 
temporary loss of pacing during RT has been described in in vitro 
experiments,65-67,77 this phenomenon to date has not been re-
ported in a clinical setting. Concerns have been raised regarding 
noise oversense during RT, potentially leading to inappropriate 
shock therapies in ICD patients, as demonstrated in vitro by Hurk-
mans et al.67 So far, inappropriate tachycardia sensing without 
shock therapy has only been reported in one ICD patient under-
going RT to femur in a series (n=15) by Elders et al.51 
 Although RT may affect the function of the generator of 
PM/ICD, the PM/ICD leads are considered to be resistant to these 
effects.41 Only one case report presented a course of RT where 
malfunction of an ICD shock lead was suspected due to direct 
irradiation, leading to device reimplantation.82 In Study III, an 
increase in pacing threshold was observed in two patients (0.4% of 
RT courses with subsequent device control), still none of the epi-
sodes required intervention. 
 
Table 8: Studies examining the effects of radiotherapy on pacemakers in vivo, published in English since 1994. 
Year Author Devices, 
n 
Tumor Beam type Beam energy Tumor 
dose, 
Gy 
Device 
dose, Gy 
Outcome Clinical 
consequences 
1994 Raitt74 1 Thyroid Neutrons NA 4.8 0.9 Uncontrollable 
ventricular pacing 
at 180 bpm. 
Corruption of the 
programming code 
of the 
microprocessor. 
Replacement of 
the device. 
2000 Tsekos63 1 Right lower 
arm and axilla 
NA NA 50.4 50.4 (in 
the field) 
Decrease in 
magnet rate, 
returning to 
normal 4 months 
later. 
None 
2001 Nibhanupudy89 1 Left breast and 
supraclavicular 
field 
Photons 6 50.4 1.82 No malfunctions. - 
2006 Ampil90 3 Lung Photons NA 20-60 NA No malfunctions. - 
2006 Mitra91 1 Right lung and 
mediastinum 
Photons NA 40 1.66 No malfunctions. - 
2008 Kapa68 8 (1 of 
them 
CRT-P) 
Head and neck; 
thorax 
Photons 6 30-
69.96 
NA 
(outside 
field) 
No malfunctions. - 
2008 Oshiro71 8 Liver; lung 
(n=1) 
Protons 155-250 36.3-77 NA 
(outside 
field) 
Reverting to 
"safety backup 
program" after 46 
Gy (n=1); 2 
episodes (after 23 
and 26 Gy) of 
changing in pacing 
frequency (n=1). 
Both devices 
successfully 
reprogrammed. 
2008 Zweng84 1 Esophagus Photons NA 30 0.11 Runaway PM. 
Change from DDD 
to AAI with a fixed 
rate of 185 bpm. 
Corruption of the 
software. 
Circulatory 
collapse. 
Replacement of 
the device. 
2010 Ferrara92 37 Various Photons 
and 
electrons 
(95.6%); Co-
60 (4.4%) 
6; 18 (59%) 8-79.2 >2 (n=5); 
<2 (n=32) 
No malfunctions. - 
2011 Croshaw53 3 Breast Photons 6 38.5 0.23-0.73 No malfunctions. - 
2011 Dasgupta93 1 Heart Photons 6 37.5 0.37 Transient 
ventricular 
undersensing. 
Devise 
successfully 
reprogrammed. 
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Year Author Devices, 
n 
Tumor Beam type Beam energy Tumor 
dose, 
Gy 
Device 
dose, Gy 
Outcome Clinical 
consequences 
2011 Soejima49 60 Various NA NA 20-74 
(range 
in the 
whole 
study) 
20.69 in 1 
patient, 
otherwise 
not 
exceeding 
4.78 
1 CRT-P was found 
initialized at 46 Gy 
and 56 Gy (treated 
with 74 Gy 15 MV 
photons for 
prostate cancer). 
Device 
successfully 
reprogrammed. 
2011 Wadasadawala94 8 Head and neck; 
breast; lung 
Co-60 (n=3); 
photons 
(n=5) 
Photons: 6 
(n=3); 15 
(n=2) 
45-70 0.14-60 
(including 
PM leads) 
No malfunctions. - 
2012 Kesek45 1 Lung Photons 6 80 48 No malfunctions. - 
2012 Kirova95 1 Thoracic spine Photons 20 30 0.3 (leads 
irradiated 
directly) 
No malfunctions. - 
2012 Makkar50 50 Various Photons; 
photons 
and 
electrons 
Photons: 6 
(n=26); 16 
(n=24). Both 
with or 
without 
electrons (6-
16 MeV) 
NA 0.844 +/-
0.997 
No malfunctions. - 
2013 Gomez72 28 Various Protons NA 46.8-
87.5 
0.13-21 
(range in 
the whole 
study) 
Reset in 2 PMs, 
both treated to 
thorax, tumor 
doses at the 
episodes 4 Gy and 
16.2 Gy, 
respectively. 
Distance from 
device to RT field 3 
cm and 0.9 cm, 
respectively. 
Both devices 
successfully 
reprogrammed. 
2014 Ampil96 2 Head and neck Photons 6 NA NA No malfunctions. - 
2014 Gossman64 67 (out 
of 107 
devices) 
Various Presumably 
photons 
Various NA <2 in 85%, 
>2 in 15%, 
not 
exceeding 
6.5 (the 
whole 
study) 
Failure at 0.3 Gy 
(n=1); 
increase in sensor 
rate during RT 
(n=1); irregular 
heartbeat leading 
to reprogramming 
(n=1); twinging in 
the chest wall 
resulting in 
respiratory arrest 
(n=1) (the whole 
study). 
Not specified in 
more detail 
2015 Zaremba97 
(Study III) 
487 (25 
CRT-P) 
Various (thorax 
36% in the 
whole study) 
MV 
photons, kV 
photons, 
electrons 
9 (IQR 6-15) 
in all 
interrogated 
devices in the 
study 
Various NA Reset or 
deprogramming 
(n=9); increase in 
atrial pacing 
threshold form 
1.25 to 2.75 V 
(n=1) out of 394 
interrogated PMs. 
Devices 
successfully 
reprogrammed. 
No device 
replacements. 
AAI = atrial pacing and sensing; bpm = beats per minute; Co = cobalt; CRT-P = cardiac resynchronization therapy pacemaker; DDD = dual chamber pacing and 
sensing; Gy = gray; IQR = interquartile range; kV = kilovolt; MeV = megaelectronvolt; MV = megavolt; PM = pacemaker. 
 
  
 22  Tomas Zaremba 
Table 9: Studies examining the effects of radiotherapy on implantable cardioverter defibrillators in vivo, published in English since 
1994. 
Year Author Devices, 
n 
Tumor Beam type Maximal 
beam energy 
Tumor 
dose, 
Gy 
Device 
dose, Gy 
Outcome Clinical 
consequences 
2002 Hoecht80 4 (3 
patients) 
NA NA NA NA NA 2 ICDs of the same 
model in the same 
patient fell into fall 
back mode at <0.5 
Gy to the ICD (RT to 
pelvis). 
The device was 
replaced due to 
the first episode. 
2004 John82 1 Left breast NA NA 50 Leads: 50, 
partial 
exposure 
of the 
generator 
Shock coil failure 
due to structural 
damage during RT 
was suspected 
(shock impedance 
>125 ohms).  
A new system 
was implanted. 
2004 Thomas85 1 Right lung Photons 18 56 NA 
(outside 
field) 
Electrical reset. Unspecified 
(asymptomatic). 
2007 Nemec83 1 Left lung NA NA 59.4 NA 
(outside 
field) 
Rapid pacing 
triggering 
polymorphic VT 
during the 3rd 
fraction of 1.8 Gy. 
Collapse 
requiring 
resuscitation. 
Device removal 
afterwards. 
2007 Sepe98 1 Larynx Photons 6 60 2.5 No malfunctions. - 
2008 Kapa68 5 Various Photons 6 18-56 NA 
(outside 
field) 
No malfunctions. - 
2008 Lau47 1 Prostate Photons 23 74 0.004 Resets during 2nd 
and 9th fractions of 
2 Gy. 
RT completed 
without other 
events. Normal 
ICD parameters 
afterwards. 
2009 Gelblum48 1+33 Various Photons; 
electrons 
(n=1); 
photons and 
electrons 
(n=1) 
6 (photons); 6 
MeV 
(electrons); 6 
MV and 9 MeV 
(photons and 
electrons); 15 
(photons, n=2) 
6-86.4 0.01-2.99 Reset in 2 patients 
treated with 15 MV 
photons, outside RT 
field. 
Devices 
successfully 
reprogrammed. 
2010 Ferrara92 8 Various Photons and 
electrons 
(95.6%); Co-
60 (4.4%) 
6; 18 (59%) 8-79.2 >1 (n=2), 
<1 (n=6) 
No malfunctions. - 
2011 Croshaw53 2 Breast Photons 6 38.5 1.01, 1.68 No malfunctions. - 
2011 Soejima49 2 Various NA NA 20-74 
(range 
in the 
whole 
study) 
NA No malfunctions. - 
2012 Makkar50 19 Various Photons; 
photons and 
electrons 
6; 16. Both 
with or 
without 
electrons (6-
16 MeV) 
NA 0.921+/-
0.726 
Partial resets in 2 
devices after 1.23 Gy 
and 0.04 Gy 16 MV 
photons to the ICD, 
respectively. 
RT completed 
successfully in 
both cases. 
2013 Dell'Oca99 1 Mediastinum Photons 6 64 <5 No malfunctions. - 
2013 Elders51 15 (17 
RT 
courses) 
Various Photons; 
photons and 
electrons 
(n=1) 
6-18 16-70 <1 6 malfunctions in 5 
RT courses at 10 and 
18 MV: invalid data 
retrieval (n=2), reset 
(n=1), inappropriate 
tachycardia sensing 
(n=1), reset and 
trend data error 9 
months after the 
reset (n=1). 
RT completed 
successfully in all 
patients. 
2013 Gomez72 14 Various Protons NA 46.8-
87.5 
(range 
in the 
whole 
0.13-21 
(range in 
the whole 
study) 
Reset after 40 Gy to 
the tumor (n=1); 
resets after 32.5 Gy 
and 47.5 Gy to the 
tumor (n=1). 
Both devices 
successfully 
reprogrammed. 
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Year Author Devices, 
n 
Tumor Beam type Maximal 
beam energy 
Tumor 
dose, 
Gy 
Device 
dose, Gy 
Outcome Clinical 
consequences 
study) Distance from device 
to RT field 5 cm and 
8 cm, respectively. 
2013 Zaremba100 
(Study II) 
5 Thorax Photons 6; 18 37 37 Converting to back-
up mode at midnight 
(n=1). 
None (animal 
study; all devices 
explanted after 
the irradiations). 
2014 Ahmed46 1 Lung Photons 15 69.6 52.4 No malfunctions. - 
2014 Gossman64 40 (out 
of 107 
devices) 
Various Presumably 
photons 
Various NA <2 in 85%, 
>2 in 15%, 
not 
exceeding 
6.5 (the 
whole 
study) 
Failure at 0.3 Gy 
(n=1); increase in 
sensor rate during 
RT (n=1); irregular 
heartbeat leading to 
reprogramming 
(n=1); twinging in 
the chest wall 
resulting in 
respiratory arrest 
(n=1) (the whole 
study). 
Not specified in 
more detail. 
2015 Zaremba97 
(Study III) 
73 (19 
CRT-D) 
Various 
(thorax 36% 
in the whole 
study) 
MV photons, 
kV photons, 
electrons 
9 (IQR 6-15) in 
all 
interrogated 
devices in the 
study 
Various NA Reset (n=3), reset 
and increase in 
pacing threshold 
(n=1) out of 59 
interrogated ICDs. 
Devices 
successfully 
reprogrammed. 
Co = cobalt; CRT-D = cardiac resynchronization therapy defibrillator; Gy = gray; ICD = implantable cardioverter defibrillator; IQR = interquartile range; kV = 
kilovolt; MeV = megaelectronvolt; MV = megavolt; RT = radiotherapy. 
 
Predictors of device malfunction 
The PM/ICD malfunctions seem to occur unpredictably as far as 
radiation dose is concerned both in vivo 45-49,51,85,97 and in vitro.65-67 
Besides the effects of radiation dose, RT beam energy has emerged 
as an important subject in several studies.48,51,69 We have clearly 
demonstrated this in Study I where a nine times higher risk of 
malfunction was observed in devices exposed to 18 MV photons 
compared with 6 MV. This was also proven to be the case in Study 
III, as beam energy ≥15 MV was the strongest predictor of PM/ICD 
malfunctions. 
 In Study III, there was also a trend of increased risk of malfunc-
tions in ICDs compared to PMs, which is in line with previous re-
ports that ICDs might be more sensitive to ionizing radiation than 
PMs.39,101 Unexpectedly, we observed that device malfunctions 
were associated with location of the RT fields below the diaph-
ragm. This might be because beam energies used below the diaph-
ragm were higher than those used above. Moreover, after adjust-
ment for beam energy, the anatomical location was not significant-
ly associated with malfunction. 
 The correlation between damaging effects of RT on PMs/ICDs 
and dose rate was suggested by Mouton et al.66 Although not 
addressed directly in later studies, this concern was discussed by 
Hurkmans et al., who underlined that the dose rate to a PM/ICD 
located outside a direct beam with a dose rate of 1-10 Gy/min at 
isocenter is expected to be <1 Gy/min, hence not posing a consi-
derable threat.41 In addition, the effects of dose rate on the device 
seem to be transient and reversible.62 The results of Study II ap-
pear in line with these considerations, as no ICD dysfunction was 
observed during the irradiation procedures. 
 Contemporary PMs/ICDs are relatively well protected against 
the effects of electromagnetic interference (EMI).13 Besides ioniz-
ing radiation, LINACs include several potential sources of EMI, such 
as couch drive motors, x-ray transformers, waveguides, power 
supplies, klystrons, or magnetrons,13 potentially leading to pacing 
inhibition, fixed rate pacing, or reprogramming.41 However, these 
effects are usually transient and are observed when the machine is 
turned on or off.102 In addition, modern LINACs are sufficiently 
shielded, and EMI typically does not pose any threats to the func-
tion of PMs/ICDs.41,103 This is supported by the findings of this 
project, especially Study III, where no events of symptomatic inhi-
bition or rapid pacing were observed during RT. 
 It is unclear whether the different PM/ICD brands differ in risk 
of RT-induced malfunctions. The spectrum of the PM/ICD manufac-
turers represented in this project was relatively broad, and some 
were represented by few devices. Therefore, we were unable to 
draw any conclusions on this aspect. 
 
Possible mechanisms 
According to the literature, the manifestations of PM/ICD malfunc-
tions can in broad terms be divided into three groups: 1) transient 
effects due to interference, occurring during the irradiation only; 2) 
reverting to backup settings (reset), recoverable after reprogram-
ming the device; and 3) permanent damage to the device.77 Hashii 
et al. grouped PM/ICD errors during RT into hard errors and soft 
errors, with hard errors representing damage to the hardware of 
the device, while soft errors consist of software alterations.69 The 
latter group can be divided into severe reset requiring reprogram-
ming of the device, moderate reset not requiring correction by the 
programmer, and minor error not detectable at interrogation and 
only recorded in the data log of the device. 
 The majority of all observed malfunctions in Studies I-III were 
electrical resets requiring reprogramming. Electrical reset, power-
on-reset or fallback to back-up mode, is a relatively well known 
phenomenon in PM/ICD technology.76,86 It is a rather adequate 
behavior of the device, indicating that an error has been de-
tected.88,104 In such case, the device switches from a software-
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controlled mode to a basic hardware-driven condition.76 The pur-
pose of this reversal is to ascertain basic pacing and an effective 
shock therapy in case of ICD.87,88,104 Electrical reset seems to pose 
no harm to the device itself, as the errors occur at software level 
without physical damage to the components, and the device can 
then usually be reprogrammed at interrogation.48,49,71,88,105 As 
demonstrated in Study II and Study III, in some of these cases, 
assistance by a manufacturer technician might be necessary.48 
 Production of high energy photons in a LINAC is accompanied 
by a generation of secondary neutrons which have a notoriously 
high capability of ionizing components of CMOS devices and induc-
ing errors and resets.75,76,106 This underpins our findings of 
PMs/ICDs failing at high beam energies. Moreover, neutron pro-
duction during electron RT is 5% and 20% of that during photon RT 
at 15 MV and 25 MV nominal energies, respectively.107,108 Thus, 
these aspects are in line with the fact that no device malfunctions 
were observed during electron or kV photon RT in Study III. 
 In contrast to soft errors, hard errors consist of structural dam-
age to the device.73 There have been only few published cases 
describing other device damages than electrical resets in relation 
to RT.51,82-84 In Study III, an increase in pacing threshold occurred in 
2 (0.4%) out of 453. Both patients were treated with 6 MV photons 
to the thorax and abdomen/pelvis, respectively. Still, as the nega-
tive effect of RT on the devices cannot be ruled out, a control 
group without exposure to RT would probably be needed to draw 
any reliable conclusions on this aspect. No deviations in lead para-
meters were observed in Study II. Hard errors seem to be observed 
more often in vitro where the devices typically are exposed to 
supratherapeutic doses of radiation.65-67 Hence, every device does 
have a threshold in radiation dose ultimately damaging the cir-
cuit.109 On the contrary, soft errors appear to be more stochastic 
and less predictable.48 
 
Safety measures 
One of the dilemmas in treating PM/ICD patients undergoing RT 
arises when a decision has to be made whether to surgically re-
move the device from the vicinity of the RT field in order to avoid 
malfunction of the PM/ICD.45,46,110 Although the removal permits 
reduction of the radiation dose to the device, every surgical inter-
vention to the PM/ICD exposes the patient to the risk of complica-
tions and is associated with increased healthcare costs.42-44,59,111,112 
In terms of device relocation prior to RT in practice, it has not been 
performed in the majority of the published patient se-
ries.48,49,51,64,72,92 In other series, the rate of device relocation varies 
between 7 and 31% of RT courses,50,68 which is higher than 3.5% 
observed in Study III. However, this comparison may be limited due 
to small sample sizes in the previous studies. The rate of reloca-
tion-related complications in Study III was in line with general 
practice.59,112 
 It is generally recommended to estimate the radiation dose to 
the PM/ICD in a patient scheduled for RT.36,38,41,103,113 While the 
devices in Studies I and II received the entire administered radia-
tion dose, the device doses were in most cases not available in 
Study III due to the retrospective design of the study. PM/ICD dose 
calculations are reported in most prospective studies,48-51,53,71,92,94 
but only in less than a half of the retrospective case se-
ries.64,68,72,90,96 Some authors recommend to supplement the esti-
mated values from treatment simulation with in vivo dosimetry,113 
while others suggest that dose estimation only has to be accurate 
enough to determine in which of the three risk categories of device 
malfunction the patient will fall, especially as in most cases the 
dose to the device will be low (<2 Gy).41 In most larger prospective 
case series, the patients were evaluated in the PM/ICD clinic ac-
cording to a predefined protocol, including controls before, during, 
and after RT. However, as demonstrated in Study III, only about a 
third of these patients are referred systematically to cardiologists 
in routine clinical practice. 
 Inactivation of antitachycardia therapies either by reprogram-
ming or application of a magnet to ICDs is recommended before RT 
in several publications.39,41,113 The purpose of magnet (≥90 gauss) 
application to ICDs is to prevent inappropriate shocks in case of 
oversense from EMI, while bradycardia pacing mode is generally 
unaffected, contrary to PMs which switch to asynchronous pacing 
mode under application of a magnet.114 Although this precaution is 
supported by some in vitro data indicating oversense in ICDs during 
RT,67 to the best of our knowledge, there have been no published 
data of inappropriate shocks during RT in ICD patients. In Study III, 
application of a magnet was documented in 10.8% of RT courses 
with ICDs, and no inappropriate shocks were described in relation 
to RT in the patients with ICDs. Gossman et al. reported that in 
3.6% of cases a magnet was applied during RT, not specifying de-
vice types in these patients.64 
 
Current safety recommendations 
Several sets of practical recommendations on safe RT in PM/ICD 
patients have been issued since the publication of AAPM TG-34 
guidelines (Table 10).36,38-41,56,103,113,115 
 After identifying that the patient scheduled for RT has a 
PM/ICD, it is usually recommended to estimate the cumulative 
radiation dose to the device, where it is essential to take the max-
imal dose to any part of the generator into account.40,56,113 Also, all 
shielding of the device should originate from the LINAC rather than 
additional shielding with lead.40,103,113 Although it has previously 
been recommended to shield the device with a lead alloy during RT 
in order to keep the dose as low as possible,14,56,103,116,117 this 
would have only a limited effect due to scatter within the patient if 
the device is outside the RT field.103 In case of direct radiation, a 
simple lead apron would be also ineffective, as 90% attenuation of 
6 MV photon beam can only be achieved by >5 cm thick lead 
shield.48 In addition, some authors recommend keeping the 
PM/ICD at least 3-5 cm from the RT field.36,40,103 
 The Heart Rhythm Society/American Society of Anesthesiolo-
gists Expert Consensus Statement mentions that usage of high-
energy photon beams might lead to device malfunctions.115 Simi-
larly, recent multidisciplinary Dutch guidelines warn of using >10 
MV photons in PM/ICD patients due to high risk of device malfunc-
tions.41 On the other hand, the radiation dose still seems to be 
underscored as the main factor in some recently published review 
articles, leaving out the significance of beam energy.118,119 
 The device evaluations performed in Study III seem to be in 
discrepancy with recent recommendations, as just 34.4% RT 
courses with ≥15 MV photons led to a subsequent device evalua-
tion in opposite to the advice to control all devices after the RT 
course.41,56,113 This proportion was higher (42.0%) when ≥15 MV 
photon beams were given above the diaphragm. 
 There have been propositions to refine the prediction of the 
clinical consequences of device malfunction during RT by classify-
ing the risk to the patient into low, medium, and high (Table 
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10).41,56 In low risk patients, it is suggested that audiovisual as-
sessment of the patient during RT fractions should be sufficient, 
and that the completed RT course should be followed by a device 
check, whereas ICDs should be interrogated weekly.41 Medium and 
high-risk patients should only be treated at institutions where 
trained staff with cardiology expertise and access to external pac-
ing are available.41,56 Weekly and daily device controls are sug-
gested in medium and high-risk patients, respectively.41 Heart 
rhythm monitoring during every RT fraction is advocated, especial-
ly in high risk patients.40,41,103,113 There seems to be no solid evi-
dence on late device malfunctions in case a PM/ICD has exhibited 
normal function during and immediately after the RT; however, 
performing additional checks during a period of up to six months 
after RT has been recommended.41 
 In terms of safety measures in ICD patients, most authors rec-
ommend to inactivate all antitachycardia functions of the ICDs at 
least during the first RT fractions, either by reprogramming the 
device or by application of a magnet to the ICD.39-41,113 However, 
this rate was relatively low in Study III (application of a magnet in 
10.8%). In addition, heart rhythm monitoring is recommended as 
soon as antitachycardia therapies are switched off.40 Provided 
there is no oversense recorded at interrogations, the therapies 
might be considered to be reactivated during the remaining frac-
tions.41 Taking the radiation dose and PM-dependency into ac-
count, surgical relocation of the device might be considered in high 
risk patients, e.g. in case of ipsilateral breast or lung tumor in a 
PM-dependent patient.39,41,56 Usage of a backup temporary PM 
during RT has been advocated,56 although not used in Study III and 
seldom described in the literature.120 
 So far, no universal PM/ICD manufacturer-specific guidelines on 
safe RT have been published, besides a couple of references to 
recommendations from the major manufacturers.39,40 One of the 
reasons is the fact that not all technical data are available in the 
public domain, and also, the devices are continuously improved.121 
According to Medtronic, their devices should be able to tolerate 
cumulative doses of 1-5 Gy depending on the model (Table 11).122 
Boston Scientific and St. Jude Medical cannot rule out that their 
devices might fail even at scatter radiation, permitting no dose 
limit to be regarded as safe.123,124 In addition, Biotronik and Med-
tronic highlight the importance of beam energy due to the damag-
ing effects of secondary neutrons with a recommendation to limit 
photon energy to 10 MV.122,125 Despite some variations, all major 
manufacturers caution against the PM/ICD being located in the RT 
field.122-125 
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Table 10: Brief overview of recommendations on safe radiotherapy in patients with pacemakers and implantable cardioverter 
defibrillators published during the last decade. 
Recommendation Sundar 200556 (PM 
only) 
Tondato 2009103 Hudson 201040 Hurkmans 201241 Langer 2012113 (ICD 
only) 
Method of device dose 
estimation 
RT planning 
calculations or 
dosimetry 
Not specified RT planning calculations 
and dosimetry 
RT planning calculations; 
dosimetry can be 
considered 
RT planning 
calculations and 
dosimetry 
Maximal PM dose Low risk if not PM-
dependent and <2 Gy; 
medium risk if PM-
dependent and <2 Gy; 
high risk if PM-
dependent and >2 Gy 
or if the PM in the RT 
field 
2 Gy <2 Gy (never >5 Gy) Low risk if not PM-
dependent and <2 Gy; 
medium risk if PM-
dependent and <2 Gy or 
if 2-10 Gy; 
high-risk if >10 Gy 
- 
Maximal ICD dose - 2 Gy <1 Gy Low risk if not PM-
dependent and <2 Gy; 
medium risk if PM-
dependent and <2 Gy or 
if 2-10 Gy; 
high-risk if >10 Gy 
As recommended 
by the ICD producer 
Limit beam energy No No No ≤10 MV No 
Device checks      
Before the RT course Yes Yes Not specified Yes if not evaluated 
within the past 3 
months 
Yes 
During the RT course Weekly in high-risk 
patients 
Routinely during RT 
(after every fraction in 
PM-dependent 
patients) 
After every fraction (at 
least weekly in non-PM 
dependent patients) 
Low risk: weekly in case 
of ICD 
Medium risk: weekly 
High risk: within 24 
hours after each fraction 
Yes (not specified in 
detail) 
After the RT course Yes Not specified Not specified Yes, including controls at 
1, 3, and 6 months after 
the completed RT 
Yes 
Inactivation of 
antitachycardia 
therapies 
- No Yes Yes Yes 
Lead shielding of the 
device 
Yes (if near the RT 
field) 
Can be considered No No No 
Heart rhythm 
monitoring during RT 
In high-risk patients Should be available in 
high-risk patients 
In PM-dependent and 
ICD patients 
In high-risk patients Yes 
Gy = gray; ICD = implantable cardioverter defibrillator; MV = megavolt; PM = pacemaker; RT = radiotherapy. 
 
Table 11: Summary of recommendations from the major PM/ICD manufacturers regarding safe radiotherapy in PM/ICD patients. 
Recommendation Biotronik125 Boston Scientific123 Medtronic122 St. Jude Medical124 
Maximal PM dose 2 Gy No safe dose (2 Gy as a 
reference) 
5 Gy No safe dose 
Maximal ICD dose 2 Gy No safe dose (2 Gy as a 
reference) 
1-5 Gy depending on the 
model 
No safe dose 
Maximal beam energy <10 MV Not stated ≤10 MV Not stated 
Device checks     
Before the RT course Yes Specific to each patient Not stated Not stated 
During the RT course Not stated Specific to each patient Yes (after each fraction if the 
recommended safe dose is 
exceeded) 
Yes (a detailed evaluation 
once or twice during the 
RT course in PM-
dependent patients) 
After the RT course Yes, including a 
supplementary follow-up 
shortly after the RT 
Yes, including subsequent 
close monitoring of the 
device function 
Yes (intensified follow-up 
schedule) 
Yes 
Inactivation of 
antitachycardia therapies 
Yes Yes Yes Yes 
Lead shielding of the device Yes All available shielding 
options, including both 
internal shielding within 
the LINAC and external 
shielding of the patient 
No (ineffective against 
neutrons) 
Not stated (reduction in 
the device dose is 
recommended) 
Heart rhythm monitoring 
during RT 
Yes As determined most 
appropriate by the 
physician team 
Not stated Yes 
Gy = gray; ICD = implantable cardioverter defibrillator; LINAC = linear accelerator; MV = megavolt; PM = pacemaker; RT = radiotherapy. 
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Main findings 
The overall aim of this study was to enlighten epidemiological 
aspects of PM/ICD patients undergoing RT and to evaluate the rate 
of malfunctions in modern cardiac rhythm devices. We also sought 
to elucidate the risk factors of these malfunctions in order to be 
able to tailor safety measures according to the risk. A short sum-
mary of the main findings is presented in the following: 
 
Study I 
 Risk of malfunction of modern electronic cardiac rhythm 
devices during RT correlates with photon beam energy. 
 During irradiations with low-energy photons, no PM/ICD 
malfunctions occurred at therapeutic doses of radiation. 
 
Study II 
 The porcine model is feasible for investigating RT effects 
on implanted cardiac rhythm devices. 
 No oversense was recorded during direct irradiations of 
modern ICDs in vivo. 
 The devices were fully functional despite radiation doses 
considerably higher than the often recommended safe 
limit of 1 Gy. 
 
Study III 
 The rate of PM/ICD patients undergoing RT in Western 
Denmark increased from 1.45 to 4.33 per 100,000 per-
son-years from 2003 to 2012. 
 Discrepancies were shown between current recommen-
dations and safety measures used in clinical practice, es-
pecially in terms of device evaluations after the RT. 
 PM/ICD malfunctions were observed in 3.1% RT courses 
and consisted predominantly of resets. 
 Beam energy seems to be the most important risk factor 
of PM/ICD malfunction during RT. 
 Radiation dose plays a lower role in inducing PM/ICD 
malfunctions than previously anticipated. 
 No PM/ICD malfunctions were observed during RT with 
electrons or kilovolt photons. 
 
Strengths and limitations 
Study I was the first study to compare head to head two photon 
beam energies as a predictor of malfunctions in directly irradiated 
modern PMs/ICDs. The study sample consisted of 12 devices, 
limited to 2 or 4 from each manufacturer. This limits the statistical 
power of the analyses. The unbalanced design of the study limited 
our ability to compare the incidence rate of all events. When col-
lapsing non-overlapping intervals to achieve a balanced design, 
some information will be lost. No direct telemetry or monitoring of 
device output was performed during the irradiations. Minor soft-
ware errors, possibly not reported at interrogations by the clinical 
programmer, could have been missed. Measurements of neutron 
doses were not performed in this study. 
 In Study II, an animal model was applied for the first time in the 
field of RT and PMs/ICDs, bringing the experimental setup close to 
a clinical setting. However, the study size is limited. Also, the ani-
mals had to be euthanized immediately after the study, as a radia-
tion dose of 37 Gy delivered during 1 day would be expected to 
result in a severe radiation injury. In this study, the radiation frac-
tions were delivered faster than in the clinical situation. The reason 
for this was that a prolonged in vivo experiment lasting several 
weeks with daily irradiations and general anesthesia would be 
poorly tolerated by the animals. 
 To our knowledge, Study III is the largest study on RT in PM/ICD 
patients published to date. The population-based design allowed 
us to include all PM/ICD patients receiving RT in Western Denmark 
over a period of 10 years. In this study, the proportion of RT pa-
tients having a PM/ICD was not examined. Neither the radiation 
dose to the device nor the distance from the RT field to the 
PM/ICD were generally available in the medical records. Therefore, 
the anatomical location of the RT was used as a surrogate marker 
in the statistical model. Due to high mortality among the patients, 
approximately one third of devices were never controlled after RT. 
Being outside the scope of the study, the causes of death were not 
analyzed. Thus, we may have underestimated both the occurrence 
and degree of severity of RT-induced device malfunctions. On the 
other hand, as beam energy and proportion of ICDs were lower in 
RT courses without control, we find it unlikely that we underesti-
mated the occurrence to a major extent. 
 In this study, we can neither rule out transient asymptomatic 
effects of radiation on the devices that were not detectable at 
subsequent PM/ICD controls. The subject of RT in PM/ICD patients 
was approached from a clinical and epidemiological perspective, 
and no dosimetric measurements were performed. Neither were 
we able to asses in technical detail the changes of the CMOS in the 
devices that exhibited malfunctions during the irradiations. Finally, 
the studied beam types were limited to photons and electrons. 
 
Future perspectives 
Reduction in neutron contamination during high-energy photon 
beaming and circuit hardening against errors might be among the 
possible approaches to prevent software-based PM/ICD malfunc-
tions. We could also suggest manufacturers to consider a built-in 
“safe-RT” approach in the devices. This could be a hardware-based 
pacing mode running on especially radiation-resistant components 
of the circuit. It could be activated prior to RT, similarly to MRI-
dedicated mode in some models. This could possibly avoid erratic 
and unexpected switching of the device to fall-back settings. 
 In our opinion, further studies on RT and PMs/ICDs should also 
include close imitations of real clinical scenarios, and the animal 
model seems to allow experiments that can serve as an interim 
step between in vitro and clinical studies. Furthermore, as device 
malfunctions during RT are relatively rare, large study populations 
may be needed, and therefore, a web-based registry of PM/ICD 
patients undergoing RT could be an option.40,118 
 In the waiting time for an update on international guidelines on 
safe RT in this patient group, the following suggestions could be 
advocated by the authors (Figure 9): 
1) device relocation before RT is usually unnecessary as 
PM/ICD malfunctions only weakly correlate with radia-
tion dose; 
2) inactivation of antitachycardia therapies during RT as 
well as heart rhythm monitoring might be redundant; 
3) patients undergoing RT with electrons or kV photons 
normally do not need supplementary device evaluations 
in PM/ICD clinic; 
4) as the malfunctions mainly consist of resets, some safety 
measures such as repeated visits at PM/ICD clinic might 
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be abandoned in selected cases in favor of the comfort of 
the patient; 
5) photon beam energy should be limited to ≤10 MV when 
possible. 
 
Figure 9: Flowchart of suggested safety measures during radiotherapy in patients with pacemakers and implantable cardioverter 
defibrillators. 
 
a If available, remote monitoring with daily evaluations could be considered instead of controls in the clinic. b In case the last evaluation is more than three 
months old. c Device evaluations after every fraction in case of a reset. CRT-D = cardiac resynchronization therapy defibrillator; CRT-P = cardiac 
resynchronization therapy pacemaker; ICD = implantable cardioverter defibrillator; MV = megavolt; RT = radiotherapy. 
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Conclusions
The focus of this project is RT in cancer patients with implanted 
PM/ICD. With previous data in the field mainly originating from in 
vitro experiments and smaller-scale patient series, the current 
work approaches the subject from experimental, clinical, and 
epidemiological standpoints. In accordance with theoretical expec-
tations, we highlight a substantial increase in the size of this pa-
tient group over the last decade. At times difficult to predict, 
PM/ICD malfunctions occur at a rate that is sufficient to pose a 
clinical challenge in tailoring optimal safety measures during RT in 
PM/ICD patients, and we also demonstrate that variations exist in 
applying these measures in clinic. We show that device malfunc-
tions occurring in relation to RT mainly consist of software impair-
ments eventually leading to a reset of the PM/ICD, wiping out the 
individually tailored parameters of the device. No fatal events or 
device replacements due to the malfunctions were observed in 
Study III, suggesting that the clinical consequences of these mal-
functions tend to be relatively mild. 
 We found that radiation dose plays a smaller role in inducing 
PM/ICD malfunctions than generally anticipated. As one of the 
explanations for this, we confirm the previous observations that 
beam energy is the essential factor in inducing the damaging ef-
fects on PMs/ICDs. In line with this finding, a considerable number 
of device malfunctions occurred during RT to remote anatomical 
areas, such as abdomen and pelvis, where photon beams of higher 
energy are typically used. In addition, we observed no device mal-
functions during RT with kV photons or electrons. The animal 
model in Study II proved to be feasible in investigating the effects 
of RT on heart rhythm devices and permitted us to bring the expe-
riments close to a clinical setting where we demonstrate that 
modern devices might tolerate relatively high radiation doses. 
Based on all three studies, RT may be delivered safely in carefully 
selected patients without the need to remove the PM/ICD from 
the vicinity of the RT field. On the other hand, devices can still 
malfunction even at exposure to only minimal radiation doses 
during high-energy photon RT. 
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Summary
Background and objectives 
The number of individuals with pacemakers (PMs) and implantable 
cardioverter defibrillators (ICDs) increases. Approximately 6,000 of 
these devices were implanted in Denmark in 2013. Due to the 
ageing of the world population and with age being a risk factor for 
both cardiovascular diseases and cancer, there is a concern that 
increasing numbers of PM/ICD patients will develop malignancies 
and receive radiotherapy (RT) treatment. Modern PMs/ICDs have 
been shown to be susceptible to malfunctions during RT, possibly 
posing a threat to the safety of the patient. These malfunction 
events may be difficult to predict as they seem to only weakly 
correlate with radiation dose. Some malfunctions have been re-
ported during only scatter radiation, while other devices appear to 
be able to resist high doses of direct irradiation. Little is also known 
about the size of this patient group, and in what proportion of RT 
courses PMs/ICDs eventually fail. Data on safety measures applied 
while treating PM/ICD patients with RT are scarce as well. 
 Following hypotheses were addressed by this thesis: 
 Modern PMs/ICDs can resist higher doses of ionizing rad-
iation than generally anticipated (Study I and II). 
 Animal models are feasible for studying the effects of RT 
on ICDs in vivo (Study II). 
 The rate of RT in PM/ICD patients in the general popula-
tion is increasing (Study III). 
 The usage of safety measures varies during RT in PM/ICD 
patients in clinical practice (Study III). 
 PM/ICD malfunctions can be predicted based on parame-
ters of RT and/or type of the device (Study I and III). 
 
Methods 
In Study I, 12 modern devices (10 PMs, 2 ICDs) from five different 
manufacturers were irradiated in vitro with either 6 megavolt (MV) 
photons or 18 MV photons. Reaching cumulative radiation doses to 
the device of 150 grays (Gy), the function of the devices was as-
sessed regularly during the experiment. The malfunction rate was 
then compared between the 6 MV and 18 MV groups. 
 In Study II, five pigs were implanted with a functional ICD (one 
from each major manufacturer), and a clinical scenario with an ICD 
located in the radiation field was simulated. Every device was 
irradiated with increasing doses of 6 MV and 18 MV photons with a 
cumulative device dose of 37 Gy. The functionality of the ICDs was 
controlled during and after the irradiations. 
 In Study III, after conducting a search at the Danish National 
Patient Registry, an observational study of 560 patients undergoing 
678 RT courses during 2003-2012 in Western Denmark was per-
formed. Medical records of both PM and ICD patients undergoing 
all types of external beam RT were reviewed in order to identify 
applied safety measures and recorded device malfunctions. 
 
Results 
In the in vitro study (Study I), the devices failed earlier and at a 
higher rate during irradiations with 18 MV photons compared with 
irradiations with 6 MV photons. The first malfunction during expo-
sure to 6 MV photons occurred at radiation doses considerably 
higher than used during cancer RT. The animal model (Study II) was 
feasible for investigating RT effects on implanted cardiac devices. 
All devices were fully functional during the in vivo irradiations, 
although one recoverable malfunction was observed in one of the 
ICDs. The rate of RT courses in PM/ICD patients increased 3-fold 
from 2003 to 2012 (Study III). Applied safety measures during RT in 
this patient group varies, with only at most a third of patients 
being seen at PM/ICD clinics due to the RT. PM/ICD malfunctions 
were observed in 3.1% of RT courses with beam energy being the 
strongest predictor for malfunction. There was a trend of device 
malfunctions to be more frequent in ICDs compared with PMs, 
while radiation dose was not associated with device malfunctions. 
 
Conclusion 
With an increasing number of PM/ICD patients undergoing RT, 
there is a considerable risk that these electronic devices may mal-
function during exposure to ionizing radiation. As the beam energy 
emerges as the most important predictor of PM/ICD malfunctions, 
the radiation dose plays a smaller role in inducing these effects 
than might be expected. The majority of PM/ICD malfunctions are 
transient and do not harm the overall function of the device. Varia-
tions exist in applying safety measures in these patients, and a 
tailored approach should be taken based primarily on the risk of 
PM/ICD malfunction during RT. 
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Dansk resumé
Baggrund og formål 
Antallet patienter med pacemakere (PM) og implanterbare 
kardioverterdefibrillatorer (ICD) er stigende. Alene i 2013 blev der 
indopereret omkring 6.000 af disse elektroniske apparater i 
Danmark. Da både risikoen for hjertesygdomme og cancer stiger 
med alderen og på grund af den stigende levealder, må det 
forventes at andelen af patienter med PM/ICD, som udvikler 
cancer med efterfølgende behov for stråleterapi, vil stige over tid. 
Moderne PM/ICD kan imidlertid beskadiges af de ioniserende 
stråler, som anvendes under denne behandling, hvilket potentielt 
kan bringe patienten i fare. Disse svigt af PM/ICD kan dog være 
vanskelige at forudsige, idet de ikke synes at hænge sammen med 
stråledosis. Nogle apparater påvirkes efter blot at have været 
udsat for spredt stråling, mens andre ikke viser tegn på svigt selv 
efter høj stråledosis. Desuden ved man kun lidt om, hvor stort et 
problem disse svigt reelt udgør, og om, hvilke 
sikkerhedsforanstaltninger, der bliver anvendt hos PM/ICD 
patienter under stråleterapi. 
 Formål med denne thesis var at teste følgende hypoteser: 
 Moderne PM/ICD kan tåle højere stråledosis end hidtil 
antaget (Studie I og II). 
 Dyremodel kan anvendes til at undersøge virkningen af 
stråleterapi på ICD in vivo (Studie II). 
 Antallet af stråleterapi behandlinger hos PM/ICD 
patienter i Danmark er stigende (Studie III). 
 Der er forskelle i anvendelse af 
sikkerhedsforanstaltninger under stråleterapi hos 
PM/ICD patienter (Studie III). 
 Risikoen for PM/ICD svigt under stråleterapi kan 
forudsiges med baggrund i parametre af stråleterapien 
og/eller typen af PM/ICD (Studie I og III). 
 
Metode 
I Studie I blev 12 moderne PM/ICD (10 PM, 2 ICD) fra fem 
forskellige producenter bestrålet in vitro med enten 6 megavolt 
(MV) fotoner eller 18 MV fotoner. Funktionen af PM/ICD blev 
kontrolleret under strålingerne. Samtlige devices modtog en 
kumuleret stråledosis på 150 gray (Gy), hvorefter antallet af svigt 
blev sammenlignet mellem 6 MV og 18 MV grupperne. 
 I Studie II fik fem grise indopereret en fungerende ICD enhed 
(én fra hver af de store producenter), hvorefter en klinisk situation 
med en ICD beliggende i strålefeltet blev simuleret. Hver ICD blev 
bestrålet med stigende doser af både 6 MV og 18 MV fotoner med 
en kumuleret dosis på 37 Gy til hver ICD. Funktionen af ICD 
enhederne blev kontrolleret under og efter strålingerne. 
 I Studie III indgik 560 patienter som gennemgik 678 stråleterapi 
behandlinger i Jylland i løbet af 2003-2012. Patienterne blev 
identificeret i Landspatientregistret. Deres patientjournaler blev 
gennemgået for at identificere dels anvendte 
sikkerhedsforanstaltninger, forekomst af svigt af PM/ICD og mulige 
prædiktorer for disse svigt. 
 
Resultater 
In vitro studiet (Studie I) viste, at PM/ICD svigtede tidligere og 
oftere under bestrålinger med 18 MV fotoner sammenlignet med 6 
MV fotoner. Under sidstnævnte opstod der først svigt ved en 
kumuleret stråledosis, som var væsentligt højere end den, man 
anvender ved behandling af cancer i klinikken. Studie II viste, at 
undersøgelse af funktionen af PM/ICD under stråleterapi er 
gennemførlig i en dyremodel. Samtlige ICDer var fuldt fungerende 
under in vivo bestrålingerne, selvom der efterfølgende opstod en 
midlertidig omprogrammering til nominel standard af en ICD. 
Studie III viste, at antallet stråleterapi behandlinger hos PM/ICD 
patienter er steget markant med en tredobling af antallet fra 2003 
til 2012. Der er betydelige forskelle i håndteringen af PM/ICD 
patienter under RT, og kun højst en tredjedel af patienterne bliver 
kontrolleret i PM/ICD-ambulatorier i forbindelse med stråleterapi. 
Svigt af PM/ICD som hovedsageligt bestod af omprogrammeringer 
til nominel standard opstod ved 3,1% af stråleterapi 
behandlingerne, og den stærkeste prædiktor for disse episoder var 
anvendt stråleenergi. ICDer udviste tilbøjelighed til at svigte 
hyppigere end PM, og der var ingen sammenhæng mellem 
stråledosis og PM/ICD svigt. 
 
Konklusion 
Set i lyset af stigende antal PM/ICD patienter, som gennemgår 
stråleterapi for cancer, findes der en risiko for, at disse apparater 
svigter under strålebehandling. Mens stråleenergi spiller en 
afgørende rolle i forekomst af svigt af PM/ICD, synes stråledosis at 
have mindre betydning end hidtil antaget. Hovedparten af de svigt, 
der opstår, er forbigående og medfører som regel ingen varig 
beskadigelse af PM/ICD. Der findes forskelle i praktisk håndtering 
af disse patienter, og behandlingen bør tilpasses ud fra forventede 
risiko for PM/ICD svigt under stråleterapi.
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Appendices
Appendix A 
 
Diagnosis and procedure codes used during the search in the Danish National Patient Registry in Study III 
 
ICD-10 
Presence of cardiac pacemaker, excluding loop recorder Z95.0, excluding Z95.0L 
SKS 
Pacemaker- or ICD-related intervention, excluding application of loop recorder BFC, excluding BFCA5 
NOMESCO Classification of Surgical Procedures 
Implantation or replacement of permanent transvenous cardiac pacemaker FPE 
Implantation or replacement of permanent epicardial pacemaker FPF 
Implantation of permanent cardioverter-defibrillator FPG 
Removal of permanent cardiac pacemaker or cardioverter-defibrillator FPH 
Revision of pacemaker pulse generator or electrode FPJ 
Other operations for arrhythmias and disturbances of impulse propagation FPW 
Temporary use of transvenous or epicardial pacemaker TFP00 
Codes used historically before NOMESCO Classification of Surgical Procedures 
Implantation of pacemaker 30930 
Transvenous implantation of cardiac electrode 32100 
Surgical implantation of cardiac electrode 32105 
Transvenous implantation of atrial electrode 32110 
Surgical implantation of atrial electrode 32115 
Implantation of generator (accelerator cordis) 32120 
Replacement of generator 32121 
Implantatio convertatoris cordis (defibrillator) 32122 
Replacement of transvenous electrode 32130 
Revision of electrode 32131 
Implantation, revision, and removal of defibrillator 32159 
Other pacemaker/defibrillator operation 32199 
External pacemaker 32490 
Implantationes electrodum 32600 
Implantatio acceleratoris cordis 32610 
Acceleratio cordis endocardialis (venous electrode) 32620 
Implantationes electrodum in myocardium 32640 
Excisio corporis alieni cordis (pacemaker, electrode etc.) 32660 
Replacement of pacemaker 32680 
SKS 
Planning of radiotherapy BWGA 
External radiotherapy BWGC 
ICD = implantable cardioverter defibrillator; ICD-10 = International Classification of Diseases, 10th edition; NOMESCO = Nordic Medico-Statistical Committee; 
SKS = Danish Hospital Sector Classification System. 
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Appendix B 
 
Characteristics of radiotherapy (RT) courses in Study III resulting in device malfunction versus courses 
without malfunction by device manufacturer, including courses with complete data on both the device and 
the RT (n=658) 
 
Manufacturer All RT courses 
(n=658) 
PM/ICD controlled after RT 
[n=453 (68.8%)] 
No PM/ICD malfunction [n=439 
(96.9%)]* 
PM/ICD malfunction [n=14 
(3.1%)]* 
Biotronik, n (%) 15 12 (80.0) 11 (91.7) 1 (8.3) 
Boston Scientific, n (%) 11 8 (72.7) 8 (100.0) 0 (0.0) 
CPI, n (%) 1 1 (100.0) 1 (100.0) 0 (0.0) 
Ela, n (%) 29 18 (62.1) 16 (88.9) 2 (11.1) 
Guidant, n (%) 47 31 (66.0) 31 (100.0) 0 (0.0) 
Medtronic, n (%) 267 191 (71.5) 188 (98.4) 3 (1.6) 
Pacesetter, n (%) 48 32 (66.7) 32 (100.0) 0 (0.0) 
Siemens, n (%) 4 2 (50.0) 2 (100.0) 0 (0.0) 
Sorin, n (%) 1 0 (0.0) 0 (-) 0 (-) 
St. Jude Medical, n (%) 199 134 (67.3) 126 (94.0) 8 (6.0) 
Telectronics, n (%) 1 0 (0.0) 0 (-) 0 (-) 
Ventritex, n (%) 1 1 (100.0) 1 (100.0) 0 (0.0) 
Vitatron, n (%) 34 23 (67.6) 23 (100.0) 0 (0.0) 
ICD = implantable cardioverter defibrillator; PM = pacemaker; RT = radiotherapy. *Percentages are row percentages to allow for comparison of RT courses 
without and with malfunctions. 
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Appendix C 
 
Recorded device malfunctions during radiotherapy in Study III 
 
Device 
type 
Manufacturer Model Anatomic 
area 
irradiated 
Cumulative 
tumor dose / 
number of 
fractions 
Beam type Maximal 
beam 
energy, MV 
Description 
AAI St. Jude 
Medical 
Victory SR 5610 Thorax 48 Gy/24 Photons and 
electrons (6 
MeV) 
18 Reset (and diaphragmatic pacing) 
after 10 Gy to the tumor. Device 
was relocated before RT. 
DDD Ela Symphony DR 2550 Abdomen 
and pelvis 
70 Gy/35 Photons 15 Spontaneous reprogramming to 
unipolar pacing, output 3.5 V/0.35 
ms at both leads, basic rate 60 
bpm. Dose at the event uncertain. 
DDD Ela Symphony DR 2550 Head and 
neck 
20 Gy/4 Photons 6 Program error preventing readout 
of historical data at a control 14 
days after RT, otherwise normal 
function. 
DDD Medtronic Adapta ADDR01 Thorax 30 Gy/10 Photons 6 Permanent increase in atrial pacing 
threshold from 1.25 V (before RT) 
to 2.75 V (after RT), other lead 
parameters unchanged. 
DDD St. Jude 
Medical 
Affinity DR 5330R Thorax 48 Gy/24 Photons 18 Intermittent warnings about invalid 
data since 14 Gy to the tumor, 
otherwise normal function. 
DDD St. Jude 
Medical 
Identity ADx XL DR 
5386 
Thorax 20 Gy/4 Photons 18 Reset requiring reprogramming by 
the manufacturer after 20 Gy to 
the tumor. 
DDD St. Jude 
Medical 
Victory XL DR 5816 Spine 8 Gy/1 Photons 18 Reset. 
DDD St. Jude 
Medical 
Victory XL DR 5816 Abdomen 
and pelvis 
78 Gy/39 Photons 15 Reset after 68 Gy to the tumor. 
DDD St. Jude 
Medical 
Zephyr XL DR 5826 Lower 
extremity 
8 Gy/1 Photons 15 Reset; battery parameters not 
available (“Data not read”); Fast 
Path summary: “Diagnostics 
cleared because they were invalid”. 
DDD St. Jude 
Medical 
Zephyr XL DR 5826 Abdomen 
and pelvis 
45 Gy/25 Photons 15 Reset, dose at the event uncertain. 
VVI-ICD Biotronik Lumax 540 VR-T Abdomen 
and pelvis 
78 Gy/39 Photons 6 Reset and permanent increase in 
pacing threshold to 4.4 V after 4 Gy 
to the tumor, other lead 
parameters unchanged 
DDD-
ICD 
St. Jude 
Medical 
Atlas + DR V-243 Abdomen 
and pelvis 
60 Gy/30 Photons 18 Reset requiring reprogramming by 
the manufacturer after 40 Gy. 
CRT-D Medtronic InSyncMaximo7304 Abdomen 
and pelvis 
78 Gy/39 Photons 18 Reset after 78 Gy to tumor. 
CRT-D Medtronic InSync III Marquis 
7279 
Abdomen 
and pelvis 
25 Gy/5 Photons 18 Reset during the period of RT, dose 
at the event uncertain. 
AAI = single chamber atrial pacemaker; bpm = beats per minute; CRT-D = cardiac resynchronization therapy implantable cardioverter defibrillator; DDD = 
dual chamber pacemaker; DDD-ICD = dual chamber implantable cardioverter defibrillator; Gy = gray; MeV = megaelectronvolt; ms = miliseconds; MV = 
megavolt; V = volt; VVI-ICD = single chamber implantable cardioverter defibrillator. 
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